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Abstract 
Background: Heroin dependence is a chronic relapsing disorder characterized by a 
compulsion to seek and use heroin despite the negative consequences. In addition to the 
diagnostic criteria, heroin dependence is associated with an altered function of the 
hypothalamic-pituitary-adrenal (HPA) axis and with affective disturbances and other mental 
disorders. Stress and heroin craving are considered as key motivators for heroin use. Heroin-
assisted treatment (HAT) is suitable for chronic heroin-dependent patients who do not benefit 
of other therapy forms.  
Methods: The acute effects of intravenous diacetylmorphine (DAM, pharmaceutical heroin) 
on the HPA axis response and on the emotions in heroin-dependent patients compared with 
placebo and with healthy controls were examined. Twenty-eight heroin-dependent patients in 
stable HAT and twenty age and gender matched healthy controls were recruited for a 
randomized, controlled crossover trial. Patients were administered heroin (DAM) or placebo 
(saline), healthy controls received only saline. HPA axis response was measured by 
adrenocorticotropic hormone (ACTH) and by cortisol concentrations in plasma, serum and 
saliva to three time points (before, 20 and 60 minutes after the substance administration). 
Withdrawal syndrome, craving, mood, anxiety and anger were measured before and 60 
minutes after the substance application using validated questionnaires. Plasma concentrations 
of heroin and its main metabolites were assessed using high-performance liquid 
chromatography. 
Results: Compared to placebo, DAM administration reduced withdrawal, anxiety and anger 
in heroin-dependent patients and was associated with significant decreases in the ACTH and 
cortisol concentrations (p < 0.01). After placebo, all hormone levels were significantly higher 
in patients than in healthy controls (p < 0.01). When patients received DAM, their cortisol 
concentrations did not differ from healthy controls and their ACTH levels were significantly 
lower (p < 0.01). The concurrent cocaine use had no significant influence on the HPA axis 
response. Before substance injection, heroin-dependent patients showed significantly higher 
anxiety and depression scores than healthy controls (p < 0.0001). Irrespective of the patients’ 
perceived intoxication and sedation, DAM administration was associated with a significant 
decrease in all negative emotions and in heroin craving, and with a significant increase in 
emotional well-being (p < 0.0001). When patients received DAM, they did not differ from 
healthy controls in their emotions at the end of the experiment. 
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Conclusion: Acute DAM administration suppresses the stress response, dampens craving and 
negative emotions and increases positive emotions in heroin-dependent patients in a stable 
opioid maintenance program (HAT). Patients showed normalized HPA axis responses and 
emotional states, when they received their regular DAM dose. These findings indicate that 
heroin (DAM) − considered as a stress-protective factor – contributes to the regulation of the 
stress sensitivity and emotional vulnerability in heroin-dependent patients, and thus 
underscore the clinical benefit of HAT for chronic heroin dependence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key-words:  
Heroin dependence; Adrenocorticotropic hormone (ACTH); Cortisol; Diacetylmorphine 
(DAM); Heroin-assisted treatment (HAT); Hypothalamic-pituitary-adrenal (HPA) axis; 
Craving; Negative emotions 
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1. Theoretical background 
1.1. Heroin dependence and stress 
Heroin dependence is a chronic relapsing brain disorder, characterized by compulsive heroin 
seeking and its use, despite the negative consequences (Leshner, 1997). The Diagnostic and 
Statistical Manual of Mental Disorders (DSM) and The International Statistical Classification 
of Diseases (ICD) describe substance abuse as a maladjusted pattern of substance use leading 
to significant impairment or distress, as manifested in users’ physical and mental health and 
their social life (Dilling, Mombour, & Schmidt, 2000; Sass, Wittchen, Zaudig, & Houben, 
2003). Moreover, substance dependence is characterized by tolerance (increased amounts of 
the substance to achieve the desired effect), craving (an overwhelming impulse to substance 
use), loss of control of substance use and withdrawal symptoms (aversive physical and 
psychical phenomena when substance use is disrupted). Typically, the users spend a lot of 
time with providing the substance, with using it and with recovering from its effects. The 
family and social life and the job-related functions are thereby neglected, and consequently 
they are often lost. Although the users know these negative consequences of the substance 
use, they cannot stop it.  
In heroin-dependent patients, a considerable comorbidity with other psychiatric symptoms 
and impairments has been observed (Frei & Rehm, 2002; Walter & Gouzoulis-Mayfrank, 
2014). Especially, the use of other substances (Stitzer & Sigmon, 2006), personality disorders 
(Hasin, Fenton, Skodol, Krueger, Keyes, Geier et al., 2011; Verhoul, 2001), affective 
disorders and anxiety (Merikangas, Mehta, Molnar, Walters, Swendsen, Aguilar-Gaziola et 
al., 1998) as well as subsequent physical damages (Fingerhood, 2006) have been found. 
Moreover, high criminality rates, infectious diseases, stigmatisation, social decline and 
homelessness are the consequence of chronic heroin dependence (Uchtenhagen, 2010). For 
substance use, a lifetime prevalence of 3% and 0.1–1.6% for heroin dependence is estimated 
(Crum, 2006; Kessler, Berglund, Demler, Jin, Merikangas, & Walters, 2005).  
Stress – reaction of the organisms on perceived stress factors for the purpose to cope with 
special requirements of the environment (Lazarus & Folkman, 1884) – is closely associated 
with substance use (Brown, Wisniewski, & Dobs, 2006; Walter, Dammann, Wiesbeck, & 
Klapp, 2005). Stress has been shown to increase anxiety and the secretion of 
adrenocorticotropic hormone (ACTH) and cortisol (Grillon, Duncko, Coivington, 
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Kopperman, & Kling, 2007; Sinha, Talih, Malison, Cooney, Anderson, & Kreek, 2003). 
Furthermore, in heroin-dependent patients, stress factors, drug cues and negative mood are 
associated with elevated craving and relapse (Epstein, Willner-Reid, Vahabzadeh, Mezghanni, 
Lin, & Preston, 2009; Fox, Talih, Malison, Anderson, Kreek, & Sinha, 2005; Sinha, Garcia, 
Paliwal, Kreek, & Rounsaville, 2006).  
The stress response as a function of the hypothalamic-pituitary-adrenal (HPA) axis is 
maladaptive in substance users. Whereas elevated stress hormone levels have been found in 
cocaine use (Broadbear, Winger, Cicero, & Woods, 1999), heroin – as well as other opiates 
(e.g. morphine) − is associated with a suppression of the stress hormone secretion (Walter, 
Wiesbeck, Bloch, Aeschbach, Olbrich, Seifritz et al., 2008; Walter, Wiesbeck, Degen, 
Albrich, Oppel, Schulz et al., 2011). During opioid withdrawal syndromes (opioid means 
every substance binding to opioid receptors, e.g. methadone), an activation of the HPA axis 
was observed (Brown et al., 2006; Kreek & Koob, 1998). Heroin-dependent patients, even 
after detoxification, seem to suffer from persistent hyperresponsiveness to stress factors. This 
heightened sensitivity of the hypothalamus and the pituitary gland to negative stimuli might 
contribute in part to further drug use (Kreek, LaForge, & Butelman, 2002). 
 
1.2. Therapy of heroin dependence 
The therapy of choice in heroin dependence is the maintenance treatment with methadone or 
buprenorphine (Soyka, Apelt, Lieb, & Wittchen, 2006). Methadone was developed in the 40s 
of the 20
th
 century. Initially used as an analgesic, methadone was applied from Dole and 
Nyswander at the Rockefeller University in New York for treating opioid dependence twenty 
years later (Stoller & Bigelow, 2006). To this day, 90% of the substituted opioid-dependent 
patients in Switzerland have been treated with methadone (BAG, 2014). However, there are 
patients not responding to methadone or other treatments (Uchtenhagen, 2010). Alternative 
treatment strategies thus have been considered, including the prescription of diacetylmorphine 
(DAM, pharmaceutical heroin). In Switzerland, the heroin-assisted treatment (HAT) is 
available since 1994, and also in other countries HAT produces good therapy outcomes. 
HAT-patients showed significant improvement in their physical and mental health and 
psychosocial function, and the drug associated criminality declined as well (e.g. Oviedo-
Joekes, Brissette, Marsh, Lauzon, Guh, Anis et al., 2009; Schmid & Müller, 2008; 
Uchtenhagen, 2007).  
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Of course, additionally to maintenance treatment, accompanying psychotherapy − particularly 
for heroin-dependent patients with psychiatric comorbidity − is valuable (Gerber & Walter, 
2013). In order to consider the patients’ self-destroying patterns and to make them acquire 
functional coping strategies, cognitive-behavioural interventions can be applied (Vogel, 
Petitjean, Borgwardt, Wiesbeck, & Walter, 2010). Further specific therapy methods as the 
Dialectical Behavior Therapy (DBT; Linehan, 1993) work with the patients’ negative 
emotions (Walter, 2014; Walter, Gunderson, Zanarini, Sanislow, Grilo, McGlashan et al., 
2009). Furthermore, couple and family therapy involves the patients’ social environment that 
can support them in their everyday life (Schmidt, Gastpar, & Gaebel, 2006). Motivational 
Interviewing (Miller & Rollnick, 2009) and Relapse Prevention (Marlatt & Gordon, 1985) are 
further effective interventions for getting the patients’ therapy motivation, commitment and 
long-term abstinence. Respect and estimation are thereby crucial elements of the therapeutic 
relationship.  
Psychosocial support and the integration in the working environment are important units of a 
comprehensive treatment in individuals with substance related disorders and comorbid mental 
illness (Mueser et al., as cited in Stohler, 2014). The effectiveness of pharmacological therapy 
of comorbid psychiatric disorders is given, but possible interactions of the medicaments with 
opiates must thereby be considered (Stohler, 2014).  
 
1.3. Previous research  
Previous findings have consistently shown that HPA axis function is altered in opioid 
dependence. First, Eisenman and colleagues observed reduced steroid levels in morphine-
dependent individuals. When the drug administration was stopped, the measured parameter 
raised and normalized after the acute withdrawal again (Eisenman, Fraser, & Brooks, 1961; 
Eisenman, Fraser, & Isbell, 1958). Further examinations on stress hormones secretion in 
surgery patients showed the suppressing effect of opiates as well (George, Reier, Lanese, & 
Rower, 1974). Comparisons of ACTH and cortisol plasma levels in heroin-dependent versus 
healthy individuals confirmed the modified HPA axis function in opioid dependence (Ho, 
Wen, Fung, Ng, Au, & Ma, 1977). 
A range of investigations in heroin-dependent, methadone maintained patients was realized 
from Kreek and colleagues at the Rockefeller University in New York. They repeatedly found 
a suppression of the HPA axis function in active heroin use, while an activation of the stress 
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hormones during withdrawal was observed. Furthermore, these neuroendocrinological 
anomalies normalized when middle to high methadone doses were regularly administered 
(Kreek, 1996 a; b). 
In general, it was shown that opioids have a suppressive effect on the HPA axis function. 
After methadone administration, reduced cortisol concentrations and craving were observed in 
heroin-dependent patients (Walter et al., 2008; 2011). Opioid withdrawal, on the other hand, 
is associated with elevated stress hormone levels (Camí, Gilabert, San, & De La Torre, 1992). 
The increased stress reactivity was also observed in currently abstinent, former heroin-
dependent individuals not under opioid maintenance. An appropriate long-term methadone 
maintenance treatment can help to modify the altered HPA axis function in heroin-dependent 
patients (Kreek & Koob, 1998). However, this normalization seems to be particular only. In 
noradrenergic stimulation, heroin-dependent, methadone maintained patients with additional 
cocaine use showed elevated stress hormones levels, while those without parallel cocaine 
consumption did not (Schluger, Borg, Ho, & Kreek, 2001). Furthermore, the comparison of 
heroin-dependent, methadone maintained patients with healthy controls indicated that − the 
clinical stabilization with methadone maintenance treatment notwithstanding − heroin-
dependent individuals suffer from persistent stress hyperresponsivity (Schluger, Bart, Green, 
Ho, & Kreek, 2003). 
Various studies showed an elevated anxiety and mood disturbance in individuals who 
regularly use heroin (Darke & Ross, 1997; Grenyer, Williams, Swift, & Neill, 1992). 
Conversely, it has been found that individuals with high anxiety tend to use drugs (Novak, 
Burgess, Clark, Zvolensky, & Brown, 2003; Stewart, Karp, Pihl, & Peterson, 1997). High 
anxiety has been shown to be associated with drug craving (Fox et al., 2005; Sinha et al., 
2006). Increased aversive emotions, such as anger and sadness, and an elevated vulnerability 
to maladaptive emotional regulation were observed in heroin dependence (Epstein et al., 
2009; Galynker, Eisenberg, Matochik, Gertmenian-King, Cohen, Kimes et al., 2007).  
According to this previous research, stress and negative emotions seem to play a key role in 
substance use. They are closely linked to craving and withdrawal syndrome and they build the 
motivational core for further drug use − in order to avoid or to stop aversive feelings (Baker, 
Piper, McCarthy, Majeskie, & Fiore, 2004; Wang, Zhang, Wu, Liu, Hu, Chan, & Xiao, 2010).  
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1.4. Current research issues 
Based on the previous research findings, the association between stress, negative affect and 
heroin dependence can be confirmed. However, the acute effects of heroin on the HPA axis 
function and emotional changes have not been investigated in a randomized, controlled trial 
with heroin-dependent patients in stable HAT so far. In our research group, we investigated 
the HPA axis and emotional responses of heroin-dependent patients before and after heroin 
(DAM) administration in comparison with placebo (saline), as well as their responses after 
DAM administration or placebo compared with responses of healthy controls. Complying 
with ethical guidelines, we exposed the control group to the placebo condition only.  
In Article 1, we hypothesized that DAM would suppress the stress hormone concentrations 
(ACTH and cortisol) and craving in heroin-dependent patients in contrast to elevated levels of 
these parameters during withdrawal (i.e. after administration of placebo). In Article 2, we 
expected no significant differences between ACTH and cortisol levels in heroin-dependent 
patients after administration of DAM compared with healthy people (i.e. we expected that the 
HPA axis function would normalize due to the effect of DAM). In Article 3, we hypothesized 
furthermore that heroin-dependent patients would show significant higher basal anxiety, 
depressiveness and anger compared to healthy controls. After DAM administration, we 
expected normalized emotional states in patients (i.e. no significant differences between 
measured emotions in heroin-dependent patients compared to healthy controls). After 
placebo, no changes in negative emotions in patients should be observed. 
 
2. Methods 
2.1. Study sample 
Twenty-eight patients from the Division of Substance Use Disorders of the Psychiatric 
Hospital of the University of Basel (Switzerland) were recruited. They were aged 23−58 years 
(mean age = 41.3, SD = 6.6), met the DSM-IV diagnostic criteria for opioid dependence and 
had been in heroin-assisted treatment (standardized HAT-program in JANUS-Department of 
the Psychiatric Hospital of the University of Basel, Switzerland) for 6.7 years on average (SD 
= 4.5). Inclusion criteria were: age older than 18 years, history of intravenous heroin 
dependence, on current HAT for at least 6 months and unchanged dose conditions during the 
previous 3 months. Exclusion criteria were a positive alcohol breath test and a history of 
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significant medical problems or major mental disorders (other than substance use and 
personality disorders). Patients were asked to abstain from illicit drug (other than prescribed 
heroin, DAM) and alcohol use for the duration of the study.  
Twenty age and gender matched healthy controls were recruited from the general population 
via advertisement in the same geographical area (regions Basel and Bern, Switzerland). They 
were screened using a semi-structured clinical interview in order to exclude possible mental 
or physical illness or a family history of psychiatric disorders. Criterion of exclusion were 
current or previous illicit drug use, a severe physical, neurological or mental illness 
(participants’ own or in their families), and a daily alcohol consumption of more than 20 g. 
All participants were native German speakers. They received written information on the 
examination protocol and gave their written consent. The study was approved by the local 
ethics committee. The socio-demographic and diagnostic characteristic of the study sample 
are summarized in table 1.  
Table 1. Socio-demographic and diagnostic characteristics of the study sample 
 
Experimental 
group (n=28) 
Control 
group (n=20) 
p-value 
Age, mean (SD)  100,0 41.3 (6.6) 40.3 (10.9) 0.718 
Male gender, n (%)  35,1 19 (67.9) 14 (70.0) 0.875 
Partnership, n (%) 9 (32.1) 15 (75.0) 0.003 
Employment, n (%) 11 (39.3) 20 (100.0) < 0.001 
Disability, n (%) 9 (32.1) 0 (0.0) 0.005 
Doses of DAM (mg/day)  64,9 318.6 (131.7) - - 
Duration of heroin dependence (years)   49,0 20.8 (6.6) - - 
Age at the first-time heroin use (years)  51,0 19.0 (3.4) - - 
Duration of opioid maintenance (years) 6.7 (4.5) - - 
Diagnosis of personality disorder 13 (46.4)  0 (0.0) < 0.001 
Substance use: 
 - tobacco (%) 
 - number of cigarettes/day 
 - cocaine (%) 
 - cannabis (%) 
 
28 (100.0) 
21.0 (9.1) 
15 (53.6) 
8 (28.6) 
 
20 (100.0) 
11.5 (8.2) 
0 (0.0) 
5 (25.0) 
 
1.000 
< 0.001 
< 0.001 
0.53 
SD = Standard Deviation. 
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2.2. Design and procedure 
A randomized, controlled clinical trial (RCT) with a crossover design was conducted. Over 
two sessions, all patients were submitted to both conditions (DAM and placebo). The 
sequence of the injected substances was randomized. One group (n = 14) first received their 
regular dose of DAM before the beginning of the experiment, whereas the second group (n = 
14) first received placebo (saline). Immediately after the experiment, patients received the 
other substance. One week later, the patients completed the second experimental condition 
with the opposite injections sequence. Patients were informed that they receive their regular 
dose of DAM either before or after the experiment. Furthermore, they knew that the second 
injection they obtain included an ineffective saline solution, but they were unaware of the 
injection sequence. Healthy controls participated in the placebo condition only. The study has 
been registered by the website http://clinicaltrials.gov (ID NCT01174927). 
The experiment of approximately 2.5 hours per session was performed in the morning. At the 
beginning of the experimental session, participants’ alcohol intoxication was excluded and 
urine samples were collected to indicate a possible drug use. After this, biochemical and 
psychological assessments (see below) were performed. Patients then received their first 
injection (DAM or placebo). Healthy controls were injected with 5 ml of saline. A 
presentation of stressful stimuli including decision tasks during a functional magnetic 
resonance imaging (fMRI) then followed. After the fMRI performance, biochemical and 
psychological parameters were assessed again. Patients then received the second injection 
(placebo or DAM, respectively) and all participants were compensated for their participation.  
 
2.3. Materials and measurements 
2.3.1. Bioanalytical and biochemical measurements 
As measurements of the HPA axis response, adrenocorticotropic hormone (ACTH) in plasma 
and cortisol in serum and saliva were collected at baseline (at least one hour after the 
awakening, 7.30 am), 20 minutes and 60 minutes after the substance administration. The 
concentrations of heroin and its metabolites were obtained at baseline and 3, 10 and 60 
minutes after the patients had received their DAM injection. The takings of blood samples and 
the patient-centered care were ensured by qualified specialist staff using medical materials. 
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The procedure of the salivary cortisol analyse is described by Walter et al. (2008). Saliva, 
plasma and serum samples were analysed in the medical laboratory of the University Hospital 
of Basel (Switzerland) using Immulite tests (Siemens, Germany). The concentrations of DAM 
and its metabolites (6-acetylmorphine = 6AM, morphine = M, morphine-3-β -D-glucuronide 
= M3G and morphine-6-β-D-glucuronide = M6G) were measured in venous ammonium-
heparinized plasma obtained from 23 patients at baseline and 3, 10 and 60 minutes after the 
individualized heroin (DAM) injection. The analyses were performed in the Department of 
Clinical Research of the University of Bern (Switzerland). Sample preparation and 
instrumental conditions are described in detail by Bourquin, Bundeli, Lehmann and 
Brenneisen (1999).  
 
2.3.2. Psychological measurements 
Structured Clinical Interview for DSM-IV for DSM-IV Axis II Disorders (SCID-II) (First, 
Gibbon, Spitzer, Williams, & Benjamin, 1997) was used to assess the diagnosis of a comorbid 
personality disorder. The Heroin Craving Questionnaire (HCQ) was assessed to measure 
craving (Tiffany, Fields, Singleton, Haertzen, & Henningfield, 1993). The corresponding 
scale contains 9 items and measures the desire to use heroin. The State-Trait Anxiety 
Inventory (STAI) with two 20-item scales was administered to examine participants’ anxiety 
(Spielberger, 1983). The state anxiety fluctuates over time and can vary in its intensity, while 
the trait anxiety indicates a relatively stable attribute that refers to the individual tendency to 
respond with anxiety to threats perceived in the environment. The 57-item State-Trait Anger 
Expression Inventory-2 (STAXI) was used to assess the intensity of anger as an emotional 
state and the degree of the disposition to experience angry feelings as a personality trait 
(Spielberger, 1988). The Beck Depression Inventory (BDI), in the clinical practice frequently 
applied self-report tool with 21 items, was used to assess the depressiveness (Beck, Erbaugh, 
Ward, Mock, & Mendelsohn, 1961). The 60-item Likert-scale short version of the Adjective 
Mood Rating Scale (AMRS, Janke & Debus, 1978) was used to assess the emotional 
excitation and well-being. For all applied questionnaires, good validity and reliability have 
consistently been demonstrated.  
In order to detect possible placebo effects, 3 minutes after the substance administration the 
patients were asked which substance they believed they had received − DAM or placebo. 
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Additionally, both subjective drug effects and withdrawal symptoms were measured using a 
visual analogue scale (VAS) (0 = none, 10 = very strong). 
 
2.4. Statistical analyses 
For testing the hypothesis in article 1, the following statistical methods were applied: a two-
factorial repeated-measures analysis of variance (ANOVA) with two within-subject 
substances (DAM and placebo) and the between-subjects group membership (sequence of the 
administered substances) was calculated for each of the HPA axis outcome variables (plasma 
ACTH, serum cortisol and salivary cortisol concentrations). Cocaine use was included in the 
analyses as a covariate. In order to take the large range of the individual baseline hormone 
levels into account, ANOVAs were carried out with the differences between the baseline and 
post-trial measurements (i.e. before and 60 minutes after substance injection). To evaluate the 
stress hormone changes across the three measurement points under both conditions (baseline, 
20 and 60 minutes after substance injection), pairwise contrasts of the hormone levels were 
calculated. Friedman’s ANOVA with Wilcoxon signed-rank post hoc tests (a non-parametric 
analysis) was calculated for the non-normally distributed variables. To correct for the α-error 
accumulation, the Bonferroni correction was used. Psychometric data (HCQ scores and 
subjective ratings of drug effects and withdrawal symptoms) were analysed with the t-test 
and, where appropriate, with a non-parametric test (Wilcoxon signed-rank test) for dependent 
samples. The two-tailed significance level was set to p < 0.05. 
In article 2, a repeated-measures ANOVA with two within-factors substance (DAM vs. 
placebo) and three time points (baseline, 20 and 60 minutes after substance injection) was 
calculated. The factor order of the substance was randomized between subjects. As covariates, 
the random order of substance administration, age, sex and personality disorder diagnosis 
were used. The Tukey post hoc tests were performed, when within-factors were significant. 
To protect against violations of sphericity, repeated-measures data were adjusted, where 
appropriate, for within-factor degrees of freedom using the Greenhouse-Geisser correction. 
The differences between patients and healthy controls were tested with t-test for the three 
primary endpoints (plasma ACTH, serum cortisol and salivary cortisol). Because of multiple 
comparisons, alpha was adjusted for 7 tests using the Bonferroni correction. As a 
consequence, all statistical tests were considered significant at a two-tailed level of p < 
0.0072.  
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To examine the assumptions about group differences in trait variables at baseline (depression 
score, trait anxiety, trait anger) in article 3, a one-way analysis of variance (ANOVA) with 
three group levels (DAM, placebo, controls) was calculated. State variables were analyzed by 
repeated-measures ANOVA with two time points (at baseline and 60 minutes later), with 
within-subjects or group factors (DAM, placebo, controls) and a between-subjects factor. The 
order of the substance administration was randomized between subjects. The levels of 
intoxication and sedation were used as covariates. To protect against violations of sphericity, 
repeated-measures data were adjusted for within-factor degrees of freedom using the Huynh-
Feldt corrections, where appropriate. Where the within-subject factor was significant, post-
hoc planned t-tests comparisons were performed to identify the significant differences. All 
statistical tests were considered significant at a two-tailed level of p < 0.05.  
Descriptive data were analyzed by means of unpaired t-tests for continuous variables and χ2 
tests for discrete variables. All analyses were computed with the statistical program SPSS for 
Windows (versions 17.0 and 19.0) and the graphs were created with the program SigmaPlot 
11.0.  
 
3. Results 
3.1. Subjective drug effects, withdrawal symptoms and heroin craving 
As expected, patients reported significantly more drug effects and fewer withdrawal 
symptoms after injection of DAM as after placebo (p < 0.0001). Only one placebo effect was 
observed (i.e. one patient rated saline as DAM).  
As displayed in figure 1, no significant differences between HCQ scores at baseline (i.e. 
before any substance administration) were found (p > 0.05). Before and after placebo 
injection, HCQ scores did not differ significantly (p > 0.05). After DAM administration, 
craving dropped significantly over time (t = 5.19, d.f. = 27, p < 0.0001). Compared with 
placebo, significantly lower craving was reported at the end of the experimental session when 
patients received DAM (t = -5.63, d.f. = 27, p < 0.0001). 
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Figure 1. Patients’ subjective craving (Desire to Use Heroin scale, HCQ) before and after 
substance administration. Means and standard errors are displayed. *** = p < 0.0001, n.s. = 
not significant. 
 
At the end of the experiment (i.e. 60 minutes after substance injection), HCQ scores were 
significantly correlated with changes in the ACTH secretion. As expected, major heroin 
craving was positively related with increased ACTH concentrations when patients received 
placebo (r = 0.30, p < 0.05). No other significant correlation was found between the 
subjective craving scores and the hormonal stress response (p > 0.05).  
 
3.2. Plasma concentrations of heroin and its metabolites 
Heroin (DAM) peak plasma concentrations were up to 1005 ng/ml at 3 minutes after DAM 
administration, due to the very short plasma elimination half-life of the substance. DAM 
(35−139 ng/ml) was still measurable in 3 patients at the last time point of measurement (60 
minutes after injection). 6AM exhibited a concentration profile similar to DAM. M was 
*** 
n.s. 
*** 
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detectable in all patients and at all sampling time points after the administration of DAM, with 
a peak plasma concentration at 3 minutes (20 patients) and 10 minutes (3 patients). The 
decline in the plasma concentrations of M was considerably slower than the decrease 
observed for DAM and 6AM, which reflect the much longer elimination half-life for M 
compared to the acetylated compounds. At 3, 10 and 60 minutes, the concentration ranges 
were at 39−3885, 31−761, and 29−436 ng/ml, respectively. This indicates relatively stable 
plasma levels of M over a prolonged time period, with the highest inter-individual variability 
observed at 3 minutes. The M3G and M6G plasma concentrations steadily increased over the 
study period of 60 minutes and approached a plateau at the end of the experiment. 
Concentrations measured for M3G at the last sampling time point were between 281 and 4432 
ng/ml. Considerably lower concentrations were found for M6G, ranging between of 81 and 
1099 ng/ml. The plasma profiles of heroin and its metabolites are depicted in figure 2. 
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Figure 2: Plasma concentrations of heroin (diacetylmorphine, DAM) and its main metabolites 
in heroin-dependent patients before and after DAM injection. Means and standard errors are 
displayed. 
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3.3. Effects of heroin on HPA axis activity 
3.3.1. ACTH and cortisol levels in patients  
According to the analyses in article 1, DAM significantly suppressed the hormone 
concentrations: FACTH(1, 25) = 8.54, p = 0.007; Fcortisol serum(1, 25) = 30.69, p < 0.0001; Fcortisol 
saliva(1, 25) = 11.83, p = 0.002. As seen in table 2, no significant effects of cocaine use or 
group membership on the hormone levels were observed (p > 0.05).  
Table 2. ANOVA for the effects of the substance (diacetylmorphine, DAM) on stress 
hormone levels and the interactions between substance and cocaine abuse and between 
substance and group membership 
Source SS df MS F p-value 
ACTH  
Substance 12696.98 1 12696.98 8.54 0.007 
Substance x cocaine-abuse 681.45 1 681.45 0.46 0.505 
Substance x group 960.19 1 960.19 0.65 0.429 
Error (Substance) 37151.20 25 1486.05   
Cortisol serum  
Substance 515684.12 1 515684.12 30.69 0.000 
Substance x cocaine-abuse 7042.94 1 7042.94 0.42 0.523 
Substance x group 2352.60 1 2352.60 0.14 0.711 
Error (Substance) 420064.11 25 16802.56   
Cortisol saliva  
Substance 7131.07 1 7131.07 11.83 0.002 
Substance x cocaine-abuse 3.76 1 3.76 0.01 0.938 
Substance x group 1916.02 1 1916.02 3.18 0.087 
Error (Substance) 15070.16 25 602.81   
SS = Sum of Squares; df = degrees of freedom; MS = Mean Square, x = Interaction. 
 
The pairwise comparisons of the hormone levels showed significant reductions in plasma 
ACTH, serum cortisol and salivary cortisol concentrations over time after the DAM 
administration (p < 0.0001). In the placebo-condition, only plasma ACTH increased 
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significantly, namely between 20 and 60 minutes after the injection (p < 0.01). Cortisol levels 
did not increase significantly after placebo injection (p > 0.05). No significant differences 
between the baseline hormone levels were found (p > 0.05). Figures displaying the results can 
be seen in article 1 in the appendix.  
The repeated measures ANOVA calculated in article 2 showed significant substance (DAM 
vs. saline) and time interactions for ACTH (F = 11.21, p = 0.001), serum cortisol (F = 45.59, 
p < 0.001) and salivary cortisol (F = 20.16, p < 0.001) concentrations in heroin-dependent 
patients. There were significant time effects for ACTH (F = 6.06, p = 0.014) and serum 
cortisol (F = 16.46, p = 0.001) levels. According to the post-hoc tests, ACTH decreased 
significantly from baseline to 20 minutes (F = 5.54, p < 0.05) and from 20 to 60 minutes after 
administration of DAM (F = 40.65, p < 0.0001). Serum cortisol (F = 51.50, p < 0.0001) and 
salivary cortisol (F = 12.99, p = 0.001) decreased from baseline to 20 minutes after DAM 
administration, and serum cortisol (F = 42.50, p < 0.0001) and salivary cortisol (F = 26.70, p 
< 0.0001) decreased again from 20 to 60 minutes after DAM administration. There was no 
significant influence of covarites (random order of substance administration, age, sex, 
diagnosis of personality disorder) on stress hormone levels.  
 
3.3.2. ACTH and cortisol levels in patients compared with healthy controls 
At baseline, ACTH concentrations were significantly higher in patients than in healthy 
controls (t = 2.96, df = 37.52, p = 0.005). 60 minutes after the substance administration, serum 
cortisol and salivary cortisol did not differ between heroin-dependent patients and healthy 
controls when patients received DAM. ACTH concentrations were significantly lower 60 
minutes after DAM administration in patients than in healthy controls (t = -3.55, df = 46, p = 
0.001). When patients received placebo, their ACTH (t = 4.98, df = 29.97, p < 0.0001), serum 
cortisol (t = 3.87, df = 46, p < 0.0001) and salivary cortisol (t = 4.01, df = 43.17, p < 0.0001) 
concentrations were significantly higher than in healthy controls at the end of the experiment.  
As illustration, figure 3 depicts the concentrations of salivary cortisol. Figures showing the 
differences in all measured stress hormone levels between heroin-dependent patients and 
healthy controls are shown in article 2 in the appendix. 
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Figure 3: Salivary cortisol concentrations in heroin-dependent patients before and after heroin 
(diacetylmorphine, DAM) or placebo (saline) injection and in healthy controls after saline 
injection. Means and standard errors are displayed. *** = p < 0.001, n.s. = not significant. 
 
3.4. Effects of heroin on emotions  
3.4.1 Depressiveness, trait anxiety and trait anger at baseline 
Before substance administration, heroin-dependent patients exhibited significantly higher 
depression scores than healthy controls (t = -7.10, df = 46, p < 0.0001), with an average score 
of 14 (according to BDI, the cut off score for mild depression), and a higher trait anxiety (t = -
5.75, df = 46, p < 0.0001). The trait anger score did not differ significantly between the 
groups.  
 
n.s 
*** 
Substance 
administration 
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3.4.2. Effects of heroin on state anxiety and state anger 
Repeated-measures ANOVA carried out in article 3 showed a significant time effect (F = 
13.06, p = 0.001), a significant group effect (F = 14.71, p = < 0.0001) and a significant 
interaction effect (F = 5.18, p = 0.008) for state anxiety. There were no significant effects of 
subjective intoxication or sedation. State anxiety decreased in patients after DAM 
administration (t = 6.16, df = 27, p < 0.0001), but not after placebo. After DAM, patients did 
not differ in their state anxiety from healthy controls at the end of the experiment. After 
placebo, patients showed higher state anxiety than healthy controls (t = 5.06, df = 45, p < 
0.0001).  
State anger showed a significant group effect (F = 14.71, p = < 0.0001) and a significant 
interaction effect (F = 5.18, p = 0.008). The subjective intoxication and sedation had no 
significant influence. After the administration of DAM, state anger decreased significantly in 
patients (t = 6.16, df = 27, p < 0.0001), whereas it increased after placebo (t = -2.11, df = 27, p 
= 0.044). After the placebo administration, patients showed significantly higher state anger 
than healthy controls (t = 2.83, df = 46, p = 0.007). 
 
3.4.3. Effects of heroin on mood 
A significant group effect (F = 11.70, p = < 0.0001) and a significant interaction effect (F = 
21.98, p < 0.0001) were observed for emotional excitation. The covariates intoxication and 
sedation had no significant influence. After DAM, but not after placebo, the emotional 
excitation levels in patients decreased significantly (t = 4.62, df = 27, p < 0.0001) and they 
differed no longer significantly from healthy controls (p > 0.05). Furthermore, ANOVA 
showed a significant group effect (F = 13.03, p = < 0.0001) and a significant interaction effect 
(F = 4.20, p = 0.019) for well-being as well. Also in this case, no significant influence of the 
covariates intoxication and sedation was detected. The well-being scores in patients increased 
significantly after DAM administration (t = -3.58, df = 27, p = 0.001) and patients rated their 
well-being higher after DAM than after placebo administration (t = 3.31, df = 27, p = 0.002). 
After DAM, patients’ well-being reached the level of healthy controls (p > 0.05).  
The described results of the effect of heroin on emotions are displayed in table 2 in article 3 in 
the appendix. 
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4. Discussion  
4.1. Strengths and limitations 
The issue of the present study was to examine the acute effects of diacetylmorphine 
(pharmaceutical heroin, DAM) on the HPA axis function and emotional state in heroin-
dependent patients. Presumably, this is the first study on effects of DAM administration on 
the HPA axis and emotional response in heroin-dependent patients compared to placebo and 
to healthy controls in a controlled experimental setting.  
The analyses showed significant decreases in ACTH and cortisol concentrations and in the 
HCQ (heroin craving) scores in heroin-dependent patients after heroin (DAM) administration 
in comparison to placebo. There was no significant interaction between the injected substance 
and additional cocaine use or between the substance and the sequence of substance 
administration, indicating that the damping of the HPA axis is due to DAM. Moreover, 
patients’ stress hormone levels after DAM administration did not differ (cortisol) or were 
even lower (ACTH) than those from healthy controls. In the placebo condition, however, the 
stress hormone levels were higher in patients than in healthy controls. Furthermore, 
irrespective of the perceived intoxication and sedation levels, negative emotions decreased, 
whereas well-being increased in heroin-dependent patients after DAM administration. When 
patients received DAM, their emotional experience did not differ from those of healthy 
controls. After placebo, levels of patients’ negative emotions were higher in comparison with 
healthy controls. These findings demonstrate the acute suppressive effect of heroin (DAM) on 
the HPA axis activity and its alleviating influence on negative emotions and heroin craving in 
chronic heroin-dependent, DAM-maintained patients. Also on stable opioid maintenance 
treatment (HAT), heroin-dependent patients seem to show a different stress responses than 
healthy people when they do not receive their regular opioid (DAM) dose.  
The observed plasma concentrations of heroin and its metabolites revealed the short half-life 
of heroin (DAM) with a plateau phase, explaining the immediate blunting effect of DAM on 
the stress hormones secretion and negative emotions. The relatively stable plasma level over a 
prolonged time period of the active metabolite morphine, however, underscores the 
suppressive effect of DAM even one hour after administration (Kosel, Noss, Hämmig, 
Wielepp, Bundeli, Heidbreder et al., 2008).  
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The elevated HPA axis response observed in heroin-dependent patients after placebo supports 
previous results showing that HPA axis activity merely partial normalized in methadone-
maintained, heroin-dependent patients compared to active and to former heroin users (Kreek 
et al., 2002). According to findings in the present study, heroin-dependent patients in HAT 
seem to need their regular DAM doses to suppress the hyperresponsiveness of the HPA axis 
sustainably. Furthermore, the elevated hormone levels (ACTH) before substance 
administration in patients compared to healthy controls probably reflects the beginnings of 
withdrawal symptoms, given that patients had not received their dose of DAM at that point of 
time. As expected, patients’ withdrawal levels decreased after DAM administration, but not 
after placebo.  
In previous studies, opioid withdrawal was associated with an elevated stress hormone 
secretion (Camí et al., 1992; Volavka, Cho, Mallya, & Baumann, 1979). In the present study, 
however, the increase in the hormone levels after placebo was only by trend. Solely ACTH 
levels increased significantly between 20 and 60 minutes after placebo injection, but the main 
time effect was non-significant as well. Hence, this finding does not support the idea that 
opioid withdrawal is associated with an activation of the HPA axis. This can possibly be 
explained by the patients’ long-standing maintenance treatment (HAT) as well as their 
knowledge that they would receive their regular DAM dose not later than at the end of the 
experiment. Although they reported withdrawal symptoms, patients may not have experienced 
intense somatic withdrawal in fact. The significant correlation between the craving scores and 
the changes in ACTH levels at the end of the experiment showed the relationship between 
patients’ subjective feeling and their endocrine response, suggesting that the greater the 
subjective withdrawal, the higher the stress hormone concentrations and vice versa. Of course, 
this relationship does not allow the conclusion, that changes in the HPA response have a 
significant impact on the subjective experience of craving. The elevated ACTH levels might 
nevertheless be a possible explanation for the higher subjective craving scores.  
In contrast to the results of the present study, Wisniewski, Brown, John, Cofranceso, Golub, 
Ricketts et al. (2006) found elevated basal cortisol levels in active drug users. According to 
the authors, these findings might reflect withdrawal symptoms during the study as well as the 
combination of heroin and cocaine commonly used by illicit drug users. Therefore, the 
regularity and availability of DAM as well as other psychological and supporting elements of 
the HAT may have been relevant factors influencing patients’ stress response, resulting in a 
relative stability of the stress hormones secretion during the experiment, even in the placebo 
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condition. Furthermore, in the present study, cocaine-dependent patients were not included in 
the recruitment and all patients who participated denied cocaine use during the last day before 
the experiment. Hence, the expected counteracting effects of cocaine – an increased activation 
of the HPA axis − (Sinha et al., 2006), were not observed here. For more clarity, the 
association between opioid withdrawal, heroin craving and HPA axis activity should next be 
examined by including heroin-dependent individuals not in stable opioid maintenance 
treatment and without concurrent cocaine use. However, the recruitment of such a sample and 
the study realization could prove difficult, due to the common polysubstance use observed by 
the majority of heroin-dependent individuals (Wisniewski et al., 2006).  
Consistent with previous findings (Wang et al., 2010), the observed higher basal levels of 
anxiety and depressiveness in heroin-dependent patients compared to healthy controls indicate 
a possible affective vulnerability with a reduced stress tolerance and a restricted ability to 
cope with emotional stress. After DAM administration, negative emotions (anxiety and anger) 
decreased significantly in heroin-dependent patients. This dampening effect on the emotional 
feeling supports the acute emotional regulation character of DAM and may therefore be a 
relevant maintaining factor in further drug use. In accordance with these results, functional 
imaging studies provided evidence for an altered processing of emotional stimuli in opioid 
users (Aguilar de Arcos, Verdejo-Garcia, Ceverino, Montanez-Pareja, Lopez-Juarez, Sanchez-
Barrera et al., 2008) and for neural alterations in their brain function and structure (Volkow, 
Fowler, & Wang, 2003; Wrege & Borgwardt, 2014). Heroin (DAM) could therefore be an 
effective instrument in correcting this maladaptive emotion regulation in heroin-dependent 
patients. Moreover, due to the observed increase in the well-being ratings after DAM 
administration, but not after placebo, heroin consumption could be considered as a kind of 
self-medication (Khantzian, 1997), as patients may use heroin in order to handle their 
emotional imbalance and stress vulnerability based on the pathological brain changes (Kalivas 
& Volkow, 2005; Volkow et. al, 2003).  
The main strength of the present study is the randomized, controlled cross-over design and the 
adequate sample size allowing the control of confounding variables and sequence effects. 
Such study design can only be realized in countries with heroin-assisted treatment (HAT) 
programs, including Switzerland. On the other hand, the stressful stimuli presented in the 
fMRI-session were not a valid stress test, as is for example the Trier Social Stress Test 
(Kirschbaum, Pierke, & Hellhammer, 1993). So far there is no standardized picture set 
regarding drugs that would be used to examine stress reactions in substance users. This 
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limitation could be mitigated by the fact that fMRI-scanning has been demonstrated to be a 
stressful experience associated with elevated cortisol concentrations in healthy people and 
depressive patients (Muehlhan, Lueken, Wittchen, & Kirschbaum, 2011; Peters, Cleare, 
Papadopoulos, & Fu, 2011). In substance use disorders, psychosocial stress is generally 
considered to be a predictive factor for relapse (Walter, Gerhard, Duersteler-MacFarland, 
Weijers, Boening, & Wiesbeck, 2006). 
 
4.2. Clinical implications 
As the present study showed, short-acting opioids such as heroin (DAM, respectively) seem 
to reduce the patients’ heightened stress responsivity, their heroin craving and aversive 
emotions. The above mentioned limitations notwithstanding, the results hence support the 
efficacy of heroin-assisted treatment (HAT) by suggesting that heroin (DAM) may contribute 
to a normalization of the hyperreactivity to stress factors and to the maladaptive emotional 
processing in heroin-dependent patients.  
Several previous studies have already provided evidence of the positive effects of DAM 
maintenance in those heroin-dependent patients, for whom methadone maintenance treatment 
(MMT) or abstinence-orientated (drug free) therapy had been unsuccessful (i.e. Rehm, 
Gschwend, Steffen, Gutzwiller, Dobler-Mikola, & Uchtenhagen, 2001; van den Brink, 
Hendricks, Blanken, Koeter, van Zwieten, & van Ree, 2003). Heroin-assisted treatment 
(HAT) is now regarded as an established treatment for severe opioid dependence in 
Switzerland and the Netherlands (Uchtenhagen, 2010). Moreover, recent research has 
indicated the efficacy of HAT even in heroin-dependent patients with no previous 
maintenance experience (Haasen, Verthein, Eiroa-Orosa, Schäfer, & Reimer, 2010). 
However, there is also a risk of negative side effects in HAT. Based on the intravenous 
administration of DAM, respiratory depression or epileptic seizure can occur (Stohler, 
Dürsteler, Störmer, Seifritz, Hug, Sattler-Mayr et al., 1999). Under medical supervision and 
professional practice of HAT, however, such incidents can be avoided. In addition to the 
injectable form, oral administration of DAM is also possible (Frick, Rehm, Zullino, Fernando, 
Wiesbeck, Amman et al., 2010). 
Apart from the direct effects of DAM, HAT may offer further stress reducing factors. The 
psychosocial support and medical care, the guaranty of the daily opioid dosis and therefore 
the reduction of drug related criminality and infectious diseases as well as the daily rhythm 
- 27 - 
 
and the room for social interchange could make an essential contribution to patients’ 
compliance and positive therapy outcome. DAM may therefore be understood as a protective 
factor helping heroin-dependent patients to counteract with their heightened stress sensitivity. 
It can furthermore be considered as a precondition for an extensive psychosocial treatment 
program, such as HAT, that supports chronic heroin-dependent patients to improve their 
general state of health and their psychosocial situation (Gerber, Borgwardt, Gerhard, Riecher-
Rössler, Wiesbeck, & Walter, 2011). 
 
4.3. Conclusion and further research 
The present study indicates that heroin (DAM) suppresses significantly the HPA axis activity 
and alleviates the negative emotions including heroin craving and withdrawal syndrome in 
chronic heroin-dependent patients in a stable opioid maintenance treatment (HAT). A regular 
DAM administration may therefore protect heroin-dependent patients against their heightened 
stress responsivity and their vulnerability to negative emotional experiences. For those 
chronic heroin-dependent patients who initially do not profit from other therapies, HAT is an 
effective treatment which complements the therapeutic options for opioid dependence, to date 
only in a few countries. Further research on the heroin (DAM) effect on the physical and 
emotional stress response in chronic heroin-dependent patients could contribute to the 
optimization of HAT and would still underscore its benefits.  
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both injections, by means of the Heroin Craving Question-
naire.  Results: Compared to saline, DAM administration in-
duced a significant decrease in plasma ACTH (p  ! 0.01), se-
rum cortisol (p  ! 0.0001) and saliva cortisol (p  ! 0.01), as well 
as in craving (p  ! 0.0001), over time.  Conclusion: Since acute 
DAM administration suppresses the stress response, DAM-
assisted treatment may be an effective alternative to metha-
done maintenance in stress-sensitive heroin-dependent pa-
tients.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Opioid dependence is a chronic relapsing brain disor-
der characterized by compulsive seeking and use of opi-
oids despite the negative consequences  [1] . Drug-related 
cues, stress or negative mood are associated with craving 
 [2–5] . Several previous studies have shown the relevance 
of stress and hypothalamic-pituitary-adrenal (HPA) axis 
dysfunction in substance use disorders  [6–11] .
 The first findings on the suppression of adrenocortical 
functions in opiate dependence were reported by Eisen-
man et al.  [12, 13] in the 1950s and 1960s in Lexington, 
 Key Words 
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 Abstract 
 Background/Aim: Heroin dependence is a chronic relapsing 
disorder characterized by the compulsion to seek and use 
heroin. Stress and craving are seen as key factors for heroin 
use. Moreover, altered hypothalamic-pituitary-adrenal (HPA) 
axis function has been frequently reported. However, the 
acute effects of diacetylmorphine (DAM) on HPA axis activity 
and craving have not been investigated in a controlled study. 
The present randomized controlled study examined wheth-
er DAM administration differs from placebo (saline) adminis-
tration with regard to HPA axis response and heroin craving. 
 Methods: In a crossover experiment, 28 DAM-maintained 
heroin-dependent patients were first injected with DAM and 
then saline, or the converse. Plasma adrenocorticotropic 
hormone (ACTH) and cortisol in saliva and serum were mea-
sured at baseline and 20 and 60 min after both injections. 
Heroin craving was measured at baseline and 60 min after 
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Ky., USA. They found reduced urinary levels of 17-keto-
steroids  [12] and reduced plasma levels of 17-hydroxycor-
ticosteroids  [13] during a period of addiction in men, in 
comparison to a phase of nonaddiction. Moreover, these 
levels increased upon discontinuation of morphine. After 
detoxification, these levels returned to the preaddiction 
range  [12, 13] , indicating that stress hormone secretion 
was depressed during opioid addiction and elevated dur-
ing withdrawal. Further research has shown that opioids 
administered during surgery suppress HPA axis activity 
 [14, 15] . Furthermore, heroin-dependent subjects exhib-
ited lower plasma levels of adrenocorticotropic hormone 
(ACTH) and cortisol when compared with healthy indi-
viduals  [14, 16] , thus providing further evidence that HPA 
axis activity is suppressed during active opioid depen-
dence. On the other hand, recent studies suggest that sub-
stance use disorders are associated with elevated cortisol 
levels and depressive symptoms  [17] . The increased HPA 
axis activity might constitute a vulnerability to the devel-
opment of substance use disorders and relapse, and this 
relationship seems to be influenced by stressful life expe-
riences  [18, 19] .
 The altered HPA axis function in substance use dis-
orders is related to early life stress  [20, 21] . Patients re-
porting childhood trauma showed increased cortisol 
and decreased ACTH concentrations during withdraw-
al, which possibly reflect a persistent blunting of the HPA 
axis function as well as its hypersensitive reaction to 
acute stress in traumatized, alcohol-dependent patients 
 [20] . Moreover, higher cortisol and ACTH plasma levels 
were found in abstinent heroin- and cocaine-dependent 
patients in comparison to healthy control subjects with-
out a history of illicit drug use and childhood trauma 
 [21] .
 Opioid withdrawal is associated with increased stress 
hormone levels  [22] . Research on opioid antagonists (e.g. 
naloxone) further supports this finding  [23, 24] . Howev-
er, elevated stress reactivity was also found in currently 
abstinent, formerly heroin-dependent individuals not 
under opioid maintenance, which could be related to 
heightened craving and relapse  [25–27] . Opioid agonists, 
on the other hand, are associated with a reduction in 
stress hormone secretion  [28, 29] . In preliminary studies, 
our group also found that opioids suppress cortisol con-
centrations in heroin-dependent patients and reduce 
craving after methadone administration  [30, 31] . 
 Although previous findings have consistently shown 
that HPA axis function is modified in heroin dependence 
and that opioids suppress stress hormone release, there 
have been few experimental studies and these have gener-
ally focused on the effects of methadone  [28, 29] . How-
ever, methadone maintenance treatment (MMT) is not 
the only treatment for severe heroin dependence, as her-
oin-assisted treatment (HAT), involving the prescription 
of pharmaceutical heroin (diacetylmorphine, DAM), 
medical attendance and psychosocial support, is also ef-
fective  [32] . Chronic heroin-dependent patients who ini-
tially do not benefit sufficiently from MMT and absti-
nence-oriented (drug-free) treatments respond well to 
treatment with DAM and improve significantly in terms 
of mental and physical health and psychosocial function-
ing, mainly assessed as reduction in crime and concur-
rent use of illegal substances  [33–39] .
 The present randomized controlled trial examined 
HPA axis function in opioid dependence after DAM ad-
ministration. Our aim was to investigate the acute effects 
of DAM on HPA axis activity, subjective craving and 
withdrawal symptoms in chronic heroin-dependent pa-
tients. We hypothesized that DAM would suppress ACTH 
and cortisol concentrations and heroin craving, in con-
trast to the increases in these parameters observed during 
withdrawal.
 Materials and Methods 
 Study Sample 
 Twenty-eight patients (67.9% men, n = 19) were recruited from 
patients at the Division of Substance Use Disorders of the Psychi-
atric Hospital of the University of Basel. They were aged 23–58 
years (mean age 41.3 years, SD 6.6), met the DSM-IV diagnostic 
criteria for opioid dependence and had been in HAT for a mean 
period of 6.7 years (SD 4.5). Exclusion criteria included a positive 
breath alcohol test and a history of significant medical problems 
or major mental disorders (other than substance use and person-
ality disorders). All patients received written information on the 
examination protocol and gave their written consent. The study 
was approved by the local ethics committee.
 Procedure 
 The present study is a part of a randomized controlled clinical 
trial. It has been registered on the website http://clinicaltrials.gov 
(ID NCT01174927). All patients were submitted to both condi-
tions in a crossover design. The sequence of the injected substanc-
es [DAM and saline (NaCl) as placebo] was randomized. One 
group (n = 14) first received their daily dose of DAM before the 
beginning of the experiment, whereas the second group (n = 14) 
first received placebo (NaCl). The patients were blinded to the 
substance. DAM was provided by the Swiss Federal Office of Pub-
lic Health in the form of the hydrochloride salt. This was dissolved 
in water (1: 9) on site and aspirated into a syringe, which was 
adapted to the evacuated infusion system. Patients of the second 
group were given their daily dose of DAM immediately after the 
experiment. The test period lasted approximately 2.5 h, including 
stressful stimuli during a functional magnetic resonance imaging 
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(fMRI) examination. One week later, the patients completed the 
alternative treatment, with the opposite sequence of substance in-
jections. Both sessions were performed in the morning.
 Biochemical Measurements 
 ACTH and cortisol were taken as measures of the stress re-
sponse. Samples were collected at baseline (at least 1 h after awak-
ening, 7.30 a.m.) and 20 min (9.00 a.m.) and 60 min after sub-
stance administration (10.30 a.m.). Salivary cortisol was analyzed 
with a time-resolved immunoassay with fluorescence detection, 
as described elsewhere  [30] . Total cortisol concentrations were 
measured in serum with the Immulite 2000 cortisol test (Siemens, 
Germany). ACTH was measured in EDTA plasma with the ACTH 
Immulite test (Siemens). Interassay and intra-assay coefficients of 
variance were below 10% for all analyses. 
 Psychological Measurements 
 Psychological data were collected at the beginning and the end 
of the experiment. The Heroin Craving Questionnaire (HCQ) 
 [40] was used to measure heroin craving. A reliability of   = 0.94 
was calculated. The corresponding scale contains 9 items and 
measures the desire to use heroin.
 In order to detect possible placebo effects, 3 min after the sub-
stance administration the patients were asked which substance 
they believed they had received, i.e. DAM or placebo. Addition-
ally, both subjective drug effects and withdrawal symptoms were 
measured using a visual analogue scale (0 = none, 10 = very strong).
 Statistical Analyses 
 For each of the outcome variables (plasma ACTH, serum cor-
tisol, salivary cortisol concentrations), a two-factorial repeated-
measures analysis of variance (ANOVA) was calculated, with two 
within-subject substances (DAM/placebo) and the between-sub-
jects group membership (sequence of the administered substanc-
es). Cocaine use was included in the analyses as a covariate. In 
order to take the large range of individual baseline hormone levels 
into account, ANOVAs were carried out with the differences be-
tween the baseline and post-trial measurements (i.e. before and 
60 min after substance injection). To evaluate the stress hormone 
changes across the 3 measurement points under both conditions 
(baseline and 20 and 60 min after substance injection), pairwise 
contrasts of the hormone levels were calculated. For the non-nor-
mally distributed variables, a nonparametric analysis (Fried-
man’s ANOVA with Wilcoxon signed-rank post hoc tests) was 
calculated. The Bonferroni correction was used to correct for the 
  -error accumulation.
 Psychometric data (HCQ scores and subjective rating of drug 
effects and withdrawal symptoms) were analyzed with the t test 
and, where appropriate, with a nonparametric test (Wilcoxon 
signed-rank test) for dependent samples. 
 All analyses were computed with the statistical program SPSS 
19.0. Graphs were created with SigmaPlot 11.0. The two-tailed sig-
nificance level was set to p  ! 0.05.
 Results 
 Demographic and Clinical Variables 
 As shown in  table 1 , 8 patients (28.6%) tested positive 
for cannabis and 15 patients (53.6%) for cocaine at one or 
both measurements. No significant differences were ob-
served between the two groups in terms of diagnostic and 
sociodemographic variables (p  1 0.05).  Table 1 gives an 
overview of the characteristics of our patient sample.
 Drug Effects, Withdrawal Symptoms and Heroin 
Craving 
 As expected, significantly more drug effects and fewer 
withdrawal symptoms were reported after injection of 
DAM than with placebo (p  ! 0.0001). Only one placebo 
effect was observed, as one patient rated NaCl as DAM.
 No significant differences between HCQ scores at 
baseline (i.e. before any substance administration) were 
found (p  1 0.05). Before and after placebo injection, HCQ 
scores did not differ significantly either (p  1 0.05). How-
ever, after DAM administration, craving dropped signif-
icantly over time (t = 5.19, degrees of freedom = 27; p  ! 
0.0001). Compared with placebo, significantly lower 
craving was reported at the end of the sequence when pa-
tients received DAM (t = –5.63, degrees of freedom = 27; 
p  ! 0.0001) ( fig. 1 ).
 At the end of the experiment (i.e. 60 min after sub-
stance injection), HCQ scores were significantly associ-
ated with changes in ACTH secretion. As expected, ma-
jor heroin craving was positively related with increased 
Table 1. S ociodemographic and diagnostic characteristics of the 
study sample (n = 28)
Characteristic Mean SD
Age, years 41.3 6.6
Male gender 19 (67.9)
Education, years 10.4 2.5
In relationship 9 (32.1)
Employed 11 (39.3)
Disability 9 (32.1)
Doses of DAM, mg/day 318.6 131.7
Methadone maintenance 13 (46.4)
Doses of methadone, mg/day 13.4 17.4
Duration of dependence, years 20.8 6.6
Age at first-time heroin use, years 19.0 3.4
Duration of opioid maintenance, years 6.7 4.5
Substance abuse
Tobacco 28 (100.0)
Number of cigarettes/day 21.0 9.1
Cocaine 15 (53.6)
Cannabis 8 (28.6)
V alues in parentheses represent percentages.
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ACTH concentrations when patients received placebo 
(r = 0.30; p  ! 0.05). No other significant correlation was 
found between the subjective craving scores and the hor-
monal stress response (p  1 0.05). 
 HPA Axis Activity 
 DAM significantly suppressed hormone concentra-
tions, as follows: ACTH, F(1, 25) = 8.54, p =  0.007; cortisol 
serum, F(1, 25) = 30.69, p  ! 0.0001, and cortisol saliva, F 
(1, 25) = 11.83, p =  0.002. No significant effects on the 
hormone levels of cocaine use or group membership were 
observed (p  1 0.05) ( table 2 ).
 The pairwise comparisons of the hormone levels 
showed significant reductions in plasma ACTH, serum 
cortisol and saliva cortisol concentrations over time after 
DAM administration (p  ! 0.0001). After placebo admin-
istration, only plasma ACTH increased significantly, be-
tween 20 and 60 min after the injection (p  ! 0.01). Corti-
sol levels did not increase significantly after placebo in-
jection (p  1 0.05). No significant differences between the 
baseline hormone levels were found (p  1 0.05) ( fig. 2–4 ).
 Discussion 
 The present study examined the acute effects of DAM 
(pharmaceutical heroin) on HPA axis function and her-
oin craving in a controlled experimental setting. There 
were significant decreases in ACTH and cortisol concen-
trations and in HCQ scores with DAM in comparison to 
placebo, demonstrating that DAM suppressed HPA axis 
activity and reduced heroin craving in chronic heroin-
dependent, DAM-maintained patients.
 The suppressive effect of opioids in general  [12–16] 
and of methadone in particular  [25, 30] on stress hor-
mone secretion and subjective craving has already been 
shown. Our recent uncontrolled study also found re-
duced cortisol concentrations in heroin-dependent pa-
tients after they had received DAM  [31] . This has now 
been confirmed for the first time in a randomized, con-
trolled, crossover study. There was no significant interac-
tion between the injected substance and concurrent co-
caine use or the sequence of administration, indicating 
that the suppression of the HPA axis is solely due to DAM 
administration, there is no significant carryover effect 
and cocaine abuse is irrelevant  [41] . Our results thus con-
firm the attenuating effect of acute opioid administration 
on the HPA axis response. Further studies should inves-
tigate whether maintenance treatment with DAM also 
normalizes diurnal stress hormone secretion in opioid-
dependent patients.
 In previous studies, opioid withdrawal was associated 
with increased stress hormone secretion  [22–24] . How-
ever, in contrast to the highly significant continuous de-
cline in the hormone concentrations after DAM admin-
istration, the increase in the hormone levels after placebo 
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 Fig. 1. Patients’ subjective craving (Desire to Use Heroin scale, 
HCQ) before and after substance administration. Means and 
standard errors are displayed.  * * *  p  ! 0.0001, n.s. = not signifi-
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 Fig. 2. ACTH concentration in DAM (heroin)-maintained pa-
tients after DAM (heroin) or placebo (saline) injection. Means 
and standard errors are displayed.  * *  p  ! 0.01,  * * *  p  ! 0.0001. 
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in our study was slight or nonsignificant. Only ACTH 
levels increased significantly between 20 and 60 min after 
placebo injection, but the main time effect was nonsig-
nificant as well. Hence, our findings do not support the 
idea that opioid withdrawal is associated with activation 
of the HPA axis. These results can possibly be explained 
by the patients’ long-standing heroin-assisted treatment 
(HAT). Moreover, patients in both groups knew that they 
would receive their daily DAM dose at the end of the ex-
periment at the latest. Although they reported withdraw-
al symptoms, they may not have experienced intense so-
matic withdrawal. Wisniewski et al.  [17] found elevated 
Table 2.  ANOVA for the effects of the substance (DAM) on stress hormone levels and the interactions between substance and cocaine 
abuse and between substance and group membership
SS d.f. MS F p value
ACTH
Substance 12,696.98 1 12,696.98 8.54 0.007
Substance ! cocaine abuse 681.45 1 681.45 0.46 0.505
Substance ! group 960.19 1 960.19 0.65 0.429
Error (substance) 37,151.20 25 1,486.05
Cortisol serum
Substance 515,684.12 1 515,684.12 30.69 0.000
Substance ! cocaine abuse 7,042.94 1 7,042.94 0.42 0.523
Substance ! group 2,352.60 1 2,352.60 0.14 0.711
Error (substance) 420,064.11 25 16,802.56
Cortisol saliva
Substance 7,131.07 1 7,131.07 11.83 0.002
Substance ! cocaine abuse 3.76 1 3.76 0.01 0.938
Substance ! group 1,916.02 1 1,916.02 3.18 0.087
Error (substance) 15,070.16 25 602.81
S S = Sum of squares; d.f. = degrees of freedom; MS = mean square; ! = interaction.
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basal cortisol levels in active drug users, which might re-
flect withdrawal symptoms during the study as well as 
the combination of heroin and cocaine commonly used 
by illicit drug users. Therefore, in our study the regular-
ity of DAM administration and its availability, as well as 
other psychological factors associated with the HAT, in-
cluding psychosocial support, may have been relevant 
factors influencing the patients’ stress response, resulting 
in relative stability of stress hormone secretion during the 
experiment, even in the placebo condition. The associa-
tion between opioid withdrawal and HPA axis activity in 
heroin-dependent patients should next be examined by 
including heroin-dependent individuals without opioid 
maintenance treatment.
 The significant correlation between the craving 
scores and the changes in ACTH levels at the end of the 
experiment showed the relationship between the pa-
tients’ subjective feeling and their endocrine response, 
suggesting that the greater the subjective withdrawal, 
the higher the stress hormone concentrations and vice 
versa. However, this relationship does not allow the con-
clusion that changes in the HPA response have a signif-
icant impact on the subjective experience of craving. 
Nevertheless, based on the consistent previous findings 
that opioid withdrawal is associated with increased 
stress hormone release  [22–24] , the elevated ACTH lev-
els might be a possible explanation for the higher subjec-
tive craving scores. 
 The advantages of the present study are its random-
ized, controlled, crossover design and the adequate sam-
ple size, which allowed for the control of confounding 
variables and sequence effects. On the other hand, the 
stressful stimuli presented in the fMRI session were not 
a valid stress test (such as the Trier Social Stress Test  [42] ). 
However, performance tasks which could be unfavorably 
evaluated by others, as used here, constitute psychologi-
cal stress, and the relevance of such tasks to increased 
cortisol and ACTH responses has already been shown 
 [43] . Most notably, fMRI scanning has been demonstrat-
ed to be a stressful experience associated with elevated 
cortisol concentrations in healthy persons and depressive 
patients  [44–46] . In substance use disorders, psychoso-
cial stress is generally considered to be a predictive factor 
for relapse  [19, 47, 48] .
 Several previous studies have established positive ef-
fects of DAM maintenance in heroin dependence in pa-
tients for whom MMT or abstinence-orientated (drug-
free) therapy had been unsuccessful  [32, 33, 35–39] . De-
spite the above-mentioned limitations, the present study 
supports the efficacy of HAT and provides potential evi-
dence for clinical implications. MMT-resistant patients 
who seem to react strongly to stress may possibly profit 
in particular from DAM maintenance. Short-acting opi-
oids (e.g. heroin) seem to lessen the heightened stress re-
activity and desire for heroin, as observed in former her-
oin users without opioid maintenance treatment  [25–27] , 
and might thereby prevent relapse with its serious conse-
quences. However, based on the intravenous administra-
tion of DAM, there is a greater risk of negative side effects 
in HAT (respiratory depression, epileptic seizure)  [36, 38, 
49] . Under medical supervision and with an adequate 
waiting period after DAM injection, such incidents can 
be avoided, so that the safety and efficacy of the treatment 
remain assured. In addition to the injectable form, oral 
administration as a tablet is possible  [50] .
 HAT is an established treatment form for severe opi-
oid dependence in Switzerland and the Netherlands  [32] . 
For those chronic heroin-dependent patients who ini-
tially do not profit from other treatments, it is an effec-
tive alternative treatment and complements the thera-
peutic spectrum for opioid dependence  [51] . Moreover, 
recent research has indicated the efficacy of HAT even in 
heroin-dependent patients with no previous mainte-
nance experience  [52] . A better understanding of the 
acute effects of DAM (heroin) would therefore promote 
the optimization of the treatment for chronic opioid de-
pendence.
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Abstract: Heroin dependence is associated with a stressful environment
and with dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis.
The present study examined the acute effects of intravenous heroin versus
placebo on the HPA axis response in heroin-dependent patients.
Twenty-eight heroin-dependent patients in heroin-assisted treatment
and 20 age- and sex-matched healthy participants were included in a con-
trolled trial in which patients were twice administered heroin or saline in
a crossover design, and healthy controls were only administered saline.
The HPA axis response was measured by adrenocorticotropic hormone
(ACTH) levels and by cortisol levels in serum and saliva before and 20
and 60 minutes after substance administration. Craving, withdrawal, and
anxiety levels were measured before and 60 minutes after substance appli-
cation. Plasma concentrations of heroin and its main metabolites were
assessed using high-performance liquid chromatography.
Heroin administration reduces craving, withdrawal, and anxiety levels
and leads to significant decreases in ACTH and cortisol concentrations
(P G 0.01). After heroin administration, cortisol concentrations did not
differ from healthy controls, and ACTH levels were significantly lower
(P G 0.01). In contrast, when patients receive saline, all hormone levels
were significantly higher in patients than in healthy controls (P G 0.01).
Heroin-dependent patients showed a normalized HPA axis response
compared to healthy controls when they receive their regular heroin
dose. These findings indicate that regular opioid administration protects
addicts from stress and underscore the clinical significance of heroin-
assisted treatment for heroin-dependent patients.
Key Words: addiction, cortisol, diacetylmorphine (DAM),
heroin-assisted treatment (HAT), heroin dependence,
hypothalamic-pituitary-adrenal (HPA) axis
(J Clin Psychopharmacol 2013;33: 00Y00)
Substance dependence is a chronic relapsing brain disorderthat is characterized by an overwhelming compulsion to
seek and use drugs, despite negative consequences.1 It is well
known that substance dependence is marked by abnormal
hypothalamic-pituitary-adrenal (HPA) axis function.2,3 An atypical
stress response occurs in both heroin and cocaine dependence.4Y6
Whereas cocaine activates the HPA axis and thus elevates
adrenocorticotropic hormone (ACTH) and cortisol levels,7 her-
oin and other opiates may suppress stress hormone secretion.8,9
HPA axis activation has been observed during opioid with-
drawal syndromes.10,11
Stress and stress response are closely associated with drug
use. Stress is known to increase drug craving, anxiety, ACTH,
and cortisol secretion and may be associated with further drug
use.12Y15
It has been argued that heroin-dependent patients suffer
from persistent hyperresponsiveness to stress, even after detox-
ification, which reflects heightened sensitivity of the hypothala-
mus and the pituitary gland to negative emotional stimuli and,
consequently, might contribute to later drug use.16
Maintenance treatment with methadone or buprenorphine is
seen as the treatment of choice in heroin dependence.17 Alterna-
tive pharmacological strategies have been considered as treatment
options, including the prescription of heroin [diacetylmorphine
(DAM)] itself. Heroin-assisted treatment (HAT) is now available
in several countries and has given good outcomes.18
Regular opioid administration could damp the inadequate
stress response of heroin-dependent patients and thus defend the
individual from aversive experiences such as negative affects.19
There is empirical evidence that the altered HPA axis func-
tion in heroin dependence partially returns to normal during opi-
oid maintenance treatment.20,21 However, some abnormalities in
the HPA axis response seem to persist even during stable opioid
maintenance treatment.22,23 This study examined the acute effects
of heroin on the HPA axis response in heroin-dependent patients,
in comparison to placebo and to healthy participants. For ethical
reasons, healthy controls were included for placebo administra-
tion only. We hypothesized that HPA axis activity would be re-
duced after heroin administration and that the HPA response in
heroin-dependent patients would be normalized in comparison
to healthy participants.
PATIENTS AND METHODS
Study Sample
Table 1 summarizes the sociodemographic and diagnos-
tic characteristics of the study sample. Twenty-eight heroin-
dependent outpatients were recruited from the Division of
Substance Use Disorders of the Psychiatric Hospital of the Uni-
versity of Basel (Switzerland). They were aged 23 to 58 years
(mean age, 41.3; SD, 6.6), met the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) diag-
nostic criteria for opioid dependence and had been in HAT for
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6.7 years on average (SD, 4.5). Their daily dose of prescribed
heroin ranged from 30 to 700 mg per day.
The inclusion criteria were age older than 18 years, history
of intravenous heroin dependence, having been on current stable
HAT for at least 6 months, and unchanged heroin dose during
the previous 3 months. Exclusion criteria were a positive alcohol
breathalyzer test and an additional physical disease or psychiatric
disorder, including other comorbid substance dependence.
In the HAT regime, heroin is administered twice a day. The
details of the HAT program in Switzerland have been described
elsewhere in more detail.24,25
When patients fulfilled the inclusion criteria, the history
of heroin and other illicit substance use was assessed with
the semistructured interview according to the International
Classification of Diseases, 10th Revision research criteria.
Patients were told to abstain from illicit drug use other than
prescribed heroin for the duration of the study, from alcohol in-
take for 72 hours and from tobacco consumption for 2 hours
before scanning. Before the experiment, the patients had no opi-
oid intake for approximately 10 hours.
The healthy controls were carefully screened using a semi-
structured clinical interview to exclude psychiatric or physical
illness or a family history of psychiatric illness. Participants
who had ever used any other illicit psychotropic drug, who con-
sumed more than 20 g alcohol per day, or who had any psychi-
atric, neurologic, or severe medical illness history, were also
excluded. Healthy controls were recruited from the general pop-
ulation by advertisement in the same geographical area. After
the study had been completely described to the subjects, written
informed consent was obtained. The study was approved by the
local ethics committee.
Study Design
The heroin-dependent patients were examined on 2 occa-
sions 1 week apart, in a crossover design. The patients were
randomly assigned after simple randomization procedures
(computerized random numbers) to 1 of 2 injected substance
(heroin vs placebo = saline). One patient group (n = 14)
received first heroin before the experiment, whereas the sec-
ond patient group (n = 14) received first saline. One week later,
they received the other substance before the experiment. All
patients were informed that they received heroin or placebo
before or after the experiment. The patients and the experi-
menter were blind to the administered substances. The healthy
controls participated only in the placebo condition. The study
has been registered by the Web site http://clinicaltrials.gov
(IDNCT01174927).
Study Procedure
The study procedure is shown in Table 2. At the start of the
study day, a urine sample was collected for screening for am-
phetamines, benzodiazepines, cocaine, methamphetamine, mor-
phine, and cannabis using immunometric assay kits. Alcohol
use was tested with an alcohol breathalyzer test.
After completion of the baseline measurement, heroin-
dependent patients received either their dose of prescribed her-
oin in 5 mL or the same dose of saline, through an indwelling
intravenous catheter during period of 30 seconds. Healthy con-
trols were injected with 5 mL of saline over 30 seconds. Heroin
was provided by the Swiss Federal Office of Public Health in
TABLE 1. Sociodemographic and Diagnostic Characteristics
of the Study Sample
Experimental
Group
(n = 28)
Control
Group
(n = 20) P
Age, mean (SD), y 41.3 (6.6) 40.3 (10.9) 0.718
Male sex, n (%) 19 (67.9) 14 (70.0) 0.875
Partnership, n (%) 9 (32.1) 15 (75.0) 0.003
Employment, n (%) 11 (39.3) 20 (100.0) G0.001
Disability, n (%) 9 (32.1) 0 (0.0) 0.005
Doses of DAM, mg/d 318.6 (131.7) V V
Methadone-equivalent
doses, mg/d
79.7 (32.8) V V
Duration of heroin
dependence, y
20.8 (6.6) V V
Age at the first-time
heroin use, y
19.0 (3.4) V V
Duration of opioid
maintenance, y
6.7 (4.5) V V
Diagnosis of personality
disorder
13 (46.4) 0 (0.0) G0.001
Substance use
Tobacco (%) 28 (100.0) 20 (100.0) 1.000
Number of
cigarettes/d
21.0 (9.1) 11.5 (8.2) G0.001
Cocaine (%) 15 (53.6) 0 (0.0) G0.001
Cannabis (%) 8 (28.6) 5 (25.0) 0.53
TABLE 2. Study Procedure
7:00 A.M. Entry in the laboratory. Screening for adherence to study protocol, medical screening,
Tox-urine tests, alcohol breathalyzer tests
7:15 A.M. Baseline assessment before substance application
7:30 A.M. Placement of intravenous catheter, baseline heroin plasma samples,
baseline hormone samples (ACTH plasma, cortisol serum, cortisol saliva)
1. Substance injection Intravenous heroin or saline administration
+ 3 min Heroin plasma samples
+ 10 min Heroin plasma samples
+ 20 min Hormone samples (ACTH plasma, cortisol serum, cortisol saliva)
+ 60 min Heroin plasma samples, hormone samples (ACTH plasma, cortisol serum, cortisol saliva)
9.00 A.M. Second assessment after substance application
2. Substance injection Intravenous saline or heroin administration
9.30 A.M. End of the experiment
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the form of the hydrochloride salt. It was dissolved in sterile
water on site and aspirated into a syringe, adapted to the evacu-
ated infusion system.26
Adrenocorticotropic hormone and cortisol were taken as
measures of the HPA axis response. Samples were collected
through an intravenous catheter at baseline, 20 and 60 minutes
after substance administration. The concentrations of heroin
and its metabolites were obtained at baseline and 3, 10, and
60 minutes after the patients had received their heroin injec-
tion. Self-report measures were assessed before and 60 minutes
after substance application.
Bioanalytical and Biochemical Measurements
The concentrations of DAM and its metabolites were mea-
sured in venous ammonium-heparinized plasma obtained from
23 patients at baseline and 3, 10, and 60 minutes after individual-
ized heroin injection. Plasma levels of DAM, 6-acetylmorphine
(6AM), morphine (M), morphine-3-A-D-glucuronide (M3G), and
morphine-6-A-D-glucuronide (M6G) were assessed using high-
performance liquid chromatography on a 125  2 mm i.d.
Nucleosil 50 C-8 ec column with a particle size of 5 Hm and a
8  3-mm i.d. precolumn packed with Nucleosil 120 C-8 and a
particle size of 3 Hm, followed by diode-array detection. Sam-
ple preparation and instrumental conditions were as described
previously in detail.27 Minor optimization steps included the
adjustment of the sample pH to 8.0 for the solid-phase extrac-
tion, to prevent DAM hydrolysis, and the multistep gradient
applied during the chromatographic separation.
Salivary cortisol was analyzed with a time-resolved immu-
noassay with fluorescence detection, as described elsewhere.8
Total cortisol concentrations were measured in serum with the
Immulite 2000 Cortisol-Test (Siemens, Germany). The mea-
surement range of the test is at 1 to 50 Kg /dL; the analytical
sensitivity is 0.20 Kg /dL. The test shows an intraassay preci-
sion of 7.4% and an interassay precision of 9.4%. The refer-
ence range of the concentration of cortisol depends on the
time of day, with morning levels of 5 to 25 Kg /dL. ACTH
was measured in EDTA plasma with the ACTH Immulite-Test
(Siemens). The intraassay precision was less than 6.1% for con-
centrations greater than 50 pg/mL; the interassay precision was
9.4% for concentrations greater than 51 pg/mL. The analytical
sensitivity of this test is 9 pg/mL. The recovery range of this
test is 91% to 107%. The median of a study with 59 test persons
in good health (male/female) performed by the manufacturer
showed a value of 24 pg/mL and a 95%-reference range of
n.d. to 46 pg/mL.
Interviews and Self-Report Measures
Clinically experienced psychiatrists conducted the Structured
Clinical Interview for DSM-IV for DSM-IV Axis II Disorders
(SCID-II)28 to assess the diagnosis of a comorbid personality dis-
order. The Heroin Craving Questionnaire was assessed to mea-
sure perceived craving and withdrawal level.29,30 The State-Trait
Anxiety Inventory was administered to examine the state anxiety.31
Statistical Analyses
Statistical analyses were conducted using SPSS for Win-
dows (version 17.0). Primary end points were the cortisol and
ACTH levels.
A repeated-measures analysis of variance (ANOVA) was
performed with the 2 within factors for substance (heroin vs
saline) and 3 time points (baseline, 20, and 60 minutes after
substance injection). The factor order of the substance was ran-
domized between subjects. The random order of substance ad-
ministration, age, sex, and personality disorder diagnosis were
used as covariates. When within factors were significant, Tukey
post hoc tests were performed. To protect against violations of
sphericity, repeated-measures data were adjusted for within-
factor degrees of freedom, using the Greenhouse-Geisser cor-
rection where appropriate.
The differences between heroin-dependent patients and
healthy controls were tested with t test for the 3 primary end
points. Because of multiple comparisons, > was adjusted for
7 tests using the Bonferroni correction. As consequence, all
statistical tests were considered significant at a 2-tailed level
of P G 0.0072.
RESULTS
Plasma Concentrations of Heroin
and Its Metabolites
Heroin (DAM) peak plasma concentrations rose to 1005 ng/mL
at 3 minutes after heroin administration, due to the extremely
short plasma elimination half-life of the drug. At the last sampling
time point, DAM (35Y139 ng/mL) was still measurable in 3 pa-
tients. 6AM exhibited a similar time-concentration profile to that
of DAM. M was detectable in all patients and at all sampling
time points after administration of DAM, with a peak plasma con-
centration at 3 minutes (20 patients) and 10 minutes (3 patients).
The decline in the plasma concentrations of M was considerably
slower than for DAM and 6AM, reflecting the much longer elim-
ination half-life for M compared to the acetylated compounds. At
3, 10, and 60 minutes, the concentration ranges were 39 to 3885,
31 to 761, and 29 to 436 ng/mL, respectively. This indicates rela-
tively stable plasma levels of M during prolonged period, with
the highest interindividual variability observed at 3 minutes. The
M3G and M6G plasma concentrations steadily increased over
the study period of 60 minutes, approaching a plateau at the end
of the study. At the last sampling time point, the M3G concentra-
tions were between 281 and 4432 ng/mL. Considerably lower
concentrations were found for M6G, ranging between of 81 and
1099 ng/mL. The plasma profiles of heroin and its metabolites
are depicted in Figure 1.
Effects of Heroin on Self-Report Measures
After the application of heroin, perceived craving (t = 5.19,
df = 27, P G 0.001) and withdrawal (t = 4.42, df = 27, P G 0.001)
decreased significantly. After saline injection, the withdrawal
level increased significantly (t = j2.83, df = 27, P G 0.01)
and craving scores did not change. The state anxiety decreased
after heroin administration (t = 6.16, df = 27, P G 0.001),
and did not change after saline. After heroin administration, pa-
tients did not differ from healthy controls in their self-report
measures.
Effects of Heroin Versus Saline in
Heroin-Dependent Patients
The repeated-measures ANOVA showed a significant sub-
stance (heroin vs saline) and time interaction for ACTH (F =
11.21, P = 0.001), serum cortisol (F = 45.59, P G 0.001) and
saliva cortisol concentrations (F = 20.16, P G 0.001) in hero-
in-dependent patients (P G 0.001). Moreover, there were signif-
icant time effects for ACTH (F = 6.06, P = 0.014) and serum
cortisol levels (F = 16.46, P G 0.001).
According to the post hoc tests, ACTH decreased signifi-
cantly from baseline to 20 minutes (F = 5.54, P G 0.05) and
from 20 to 60 minutes after heroin administration (F = 40.65,
P G 0.0001). Serum cortisol (F = 51.50, P G 0.0001) and saliva
cortisol (F = 12.99, P = 0.001) decreased from baseline to 20 min-
utes after heroin administration, and serum cortisol (F = 42.50,
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P G 0.0001) and saliva cortisol (F = 26.70, P G 0.0001) de-
creased again from 20 to 60 minutes after heroin administra-
tion. We included random order of substance administration,
age, sex, and personality disorder diagnosis as covariates in
the ANOVA. There was no significant influence on stress hor-
mone levels.
Effects of Heroin and Saline in Heroin-Dependent
Patients Versus Saline in Healthy Controls
The differences in stress hormone levels between heroin-
dependent patients and healthy controls during the experiment
are shown in Figures 2Y4. At baseline, ACTH concentrations
were significantly higher in patients than in healthy controls
(t = 2.96, df = 37.52, P = 0.005). Sixty minutes after substance
administration, serum cortisol and salivary cortisol did not
differ between heroin-dependent patients and healthy controls
when patients received heroin. ACTH concentrations were sig-
nificantly lower 60 minutes after heroin administration in heroin-
dependent patients than in healthy controls (t = j3.55, df = 46,
P = 0.001). When the heroin-dependent patients received saline,
ACTH (t = 4.98, df = 29.97, P G 0.0001), serum cortisol
(t = 3.87, df = 46, P G 0.0001), and salivary cortisol concentra-
tions (t = 4.01, df = 43.17, P G 0.0001) were significantly higher
than in healthy controls at the end of the experiment.
DISCUSSION
This study examined the acute effects of heroin on the HPA
axis response in heroin-dependent patients compared to placebo
and to healthy controls. We found that all stress hormones de-
creased in heroin-dependent patients after heroin administration.
FIGURE 1. Plasma concentrations of heroin (DAM) and its main
metabolites in heroin-dependent patients before and after heroin
injection. Means and standard errors are displayed.
FIGURE 2. ACTH concentration in heroin-dependent patients
before and after heroin or saline injection and healthy controls
after saline injection. Means and standard errors are displayed.
**P G 0.01, ***P G 0.001.
FIGURE 3. Serum cortisol concentration in heroin-dependent
patients before and after heroin or saline injection and healthy
controls after saline injection. Means and standard errors are
displayed. **P G 0.01.
FIGURE 4. Saliva cortisol concentration in heroin-dependent
patients before and after heroin or saline injection and healthy
controls after saline injection. Means and standard errors are
displayed. ***P G 0.001.
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Importantly, stress hormone levels did not differ (cortisol) or were
even lower (ACTH) than those in healthy controls when they re-
ceived heroin. However, during saline treatment, the stress hor-
mone levels were higher in patients than in healthy controls.
This finding highlights the acute suppressive effect of heroin on
the HPA axis. Moreover, it indicates thatVeven on stable opioid
maintenance treatmentVheroin-dependent patients still show a
different HPA axis response than healthy persons when they do
not receive their daily opioid dosage. We have found a higher
HPA axis response in heroin-dependent patients after saline injec-
tion than in healthy control persons. This finding supports previ-
ous results showing partial normalized HPA axis activity in
methadone-maintained heroin-dependent patients compared to
active and former heroin users.16 It could be inferred that heroin-
dependent patients in HAT need to inject their daily heroin dose
to suppress their HPA axis activity.
Before substance administration, hormone levels (ACTH)
were elevated in patients compared to controls. This probably
reflects the beginnings of withdrawal symptoms, given that
the dose of heroin had not yet been administered. After heroin
administration, but not after placebo, we found the expected
decrease in patients’ craving and withdrawal level.
The observed plasma concentrations of heroin and its me-
tabolites confirmed the very short half-life of heroin and re-
vealed a plateau phase, with relatively stable plasma levels of
the active metabolite morphine during prolonged period after
10 minutes, underscoring this acute stress suppressive effect
of heroin, even 1 hour after administration.32
The clinical consequences of this heroin effect on the HPA
axis have not been clear. However, it has been suggested
thatVin contrast to increased dopamine and opioid peptide
functionVincreased corticotropin-releasing factor and corti-
sol levels are associated with negative effects and stress like-
states in drug users.33 Additionally, animal models have shown
that acute stress induces drug-seeking behavior and drug self-
administration after prolonged abstinence, indicating the signif-
icance of stress-like states for craving and relapse.34 In animals,
this stress-induced reinforcement of drug-seeking behavior
seems to depend particularly on the activation of CRH levels
and the extended amygdale.35 In heroin-dependent patients,
the activation of the amygdala is followed by a decrease in the
activation of different brain areas, including the amygdala, after
methadone36 and buprenorphine administration.37
We demonstrated a decrease in negative affects such as anx-
iety after heroin administration. This dampening effect of negative
affectsVincluding craving and withdrawal levelVhighlights the
acute emotional regulation effect of heroin administration and
may be a relevant factor in maintaining drug-taking behavior.38
Previous studies have demonstrated the emotional regulation ef-
fect of methadone application too, but with slightly higher opioid
doses.8 Moreover, studies on intravenously injected heroin may
better reflect the pattern of drug use in heroin addicts.
Our findings suggest that heroin and other opioids may
contribute to the normalization of impaired emotional process-
ing and emphasize the benefits of regular opioid substitution
for heroin-dependent patients.39
We conclude that HPA axis activity and negative affects
can be significantly suppressed by regular opioid administra-
tion in heroin-dependent patients, which may also prevent later
illegal drug use and relapse.
Our patients were recruited from a population which mainly
consisted of individuals with long-standing polysubstance use.
Although this problem is virtually inevitable when chronic heroin-
dependent individuals are examined, it may have biased the results.
The findings may thus not apply to all groups of heroin users and
maintenance patients. We examined the effects of heroin in a con-
trolled study design that is only possible in a country that has
HAT programs. We did not have a completely balanced study
design. However, there was no significant influence of the ran-
dom order of the injected substance in the patient group.
These limitations notwithstanding, we think our results
retain significant clinical implications. They establish that hero-
in suppresses the HPA axis response and may protect stress-
sensitive heroin-dependent patients against their heightened stress
response.
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Acute Effects of Heroin on Emotions in
Heroin‐Dependent Patients
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Background: Euphoria has been described in heroin‐dependent
individuals after heroin administration. However, affective distur-
bances and disorders are common in heroin dependence. The present
study examined the acute effects of heroin on emotions in heroin‐
dependent patients.
Methods: This randomized controlled crossover trial included 28
heroin‐dependent patients (67.9% male, n ¼ 19) in stable heroin‐
assisted treatment and 20 healthy controls. The patients were
administered heroin or saline (placebo), the controls were adminis-
tered saline. Data measuring mood, affects and heroin craving (BDI,
AMRS, STAI, STAXI, and HCQ) were assessed before and
60 minutes after substance injection.
Results: Before substance injection, heroin‐dependent patients
showed significantly higher levels of anxiety and depression than
healthy controls (p < .0001). Heroin administration—but not placebo
administration—was associated with a significant decrease in all
negative emotions, including craving, and a significant increase in
emotional well‐being (p < .0001), irrespective of perceived intoxi-
cation and sedation. After the experiment, the patients did not differ
from healthy controls in their emotions, once they had received heroin.
Conclusions: Heroin dampens craving, negative emotions, and
increases positive emotions. These findings indicate that heroin
regulates emotions and underscore the clinical benefit of opioid
substitution treatment for heroin‐dependent patients. (Am J Addict
2013;XX:1–7)
INTRODUCTION
Heroin dependence is a chronically relapsing disorder that
has been characterized by a compulsion to seek and use heroin
despite negative consequences.1,2 After detoxification, a high
percentage of heroin‐dependent patients suffer a relapse into
daily drug use.3 In heroin‐dependent patients, there is a
frequent comorbidity with psychiatric disorders. In 47–97% of
these patients, psychiatric comorbidities have been found.4 In
particular, affective disorders have been frequently described
in heroin addicts.5–7 Studies have indicated that individuals
who regularly use heroin are at high risk for elevated levels of
anxiety and anxiety linked disorders.8,9 These studies suggest
an association between anxiety‐related processes and regular
heroin use, although no data is available on the process that
may underlie such a linkage. There are multiple reasons to
expect an association between anxiety sensitivity, which is
defined as the fear of anxiety‐related sensations, and chronic
heroin use.10 It has generally been found that individuals with
high levels of anxiety tend to use psychoactive substances.11–14
High levels of anxiety and stress have been found to be
associated with drug craving and drug use.15,16 In heroin‐
dependent patients, heroin craving was most robustly
associated with increases in sadness and anger.17
Thus, there seems to be a direct connection between heroin
craving and negative emotions in heroin dependencewhich can
be suppressed directly after heroin use.
Clinical observations have identified many emotion‐related
signs in the development and maintenance of drug addiction. It
has been argued that the escape and avoidance of negative
affects—manifested as specific emotion such as anxiety,
irritability, or sadness—are a key motive for further addictive
drug use.18,19 The negative emotion is the motivational core of
the withdrawal syndrome. Due to the repeated cycles of drug
use and withdrawal, substance‐dependent individuals learn to
identify interoceptive cues of negative affect preconsciously.
Hence, the motives for further substance use are not under
cognitive control.18 Galynker et al.20 presume that, even in the
absence of comorbid affective disorders, heroin‐dependent
patients may have a lasting vulnerability to emotional
dysregulation.
It has been demonstrated that maintenance treatment with
opioid agonists produces favorable treatment maintenance
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in heroin dependence.21 Opioid substitution treatment for
heroin dependence relieves heroin withdrawal, and curbs
heroin craving.22 This holds true for opioid substitution with
methadone or buprenorphine, as well as for heroin‐assisted
treatment (HAT) with diacetylmorphine (pharmaceutical
heroin, DAM), which have shown satisfactory outcomes.23–26
However, the acute effects of heroin on subjective negative
and positive emotions have not been investigated in a
randomized controlled trial with stable opioid‐maintained
patients. We hypothesized higher levels of negative emotions,
such as depressiveness, anxiety, and anger in heroin‐dependent
patients, compared to healthy controls at baseline.We expected
normalization of emotions in heroin‐dependent patients given
heroin, compared to controls. We also anticipated no change in
negative emotions after administration of placebo.
PATIENTS AND METHODS
Study Sample
Twenty‐eight patients (67.9% male, n ¼ 19) were recruited
from the Division of Substance Use Disorders of the
Psychiatric Hospital of the University of Basel (Switzerland).
They were aged 23–58 years (average age ¼ 41.3, SD ¼ 6.6),
met the DSM‐IV diagnostic criteria for opioid dependence and
had been in heroin‐assisted treatment (HAT) for 6.7 years on
average (SD ¼ 4.5).
All participants were native German speakers. The last
administration of their half‐daily dose of heroin before the
examination had taken place during the afternoon of the previous
day. Participants were told to abstain from illicit drug use other
than prescribed heroin for the duration of the study, from alcohol
intake for 72 hours, and from tobacco consumption for 2 hours
before scanning. All participants were cigarette smokers.
Inclusion criteria were: age older than 18 years, history of
intravenous heroin dependence, being on current HAT for at
least 6 months, and unchanged dose conditions during the
previous 3 months. Exclusion criteria were a positive alcohol
breathalyzer test and an additional physical disease or
psychiatric disorder, including other comorbid substance
dependence except tobacco. Patients with cocaine and
cannabis abuse who did not fulfill the criteria of substance
dependence were not excluded.
The history of heroin and other illicit substance use
was assessed with the semi‐structured interview according to
ICD‐10 research criteria. All patients had had at least two in‐
patient detoxification treatments for heroin dependence,
established opioid substitution, and had participated in the
standardized HAT program (JANUS, University of Basel,
Switzerland).
This includes the prescription of pharmaceutical DAM and
psychosocial treatment and is established in several countries
for severe heroin dependence.
The healthy controls were carefully screened, using a semi‐
structured clinical interview to exclude psychiatric or physical
illness or a family history of psychiatric illness. Controls were
also excluded who had ever used any other illicit psychotropic
drug, who consumed more than 20 g alcohol/day, or who had
any psychiatric, neurologic, or severe medical illness history.
Controls were recruited from the general population by
advertisement in the same geographical area. They were
informed that the aim of the study was to investigate the acute
effects of heroin on emotions in heroin‐dependent patients.
They were included as healthy controls, receiving a neutral
substance (saline).
After the study had been fully described to the subjects,
written informed consent was obtained. The study was
approved by the local ethics committee.
TABLE 1. Socio‐demographic and diagnostic characteristics of the study sample
Measurements
Mean (SD)
p‐Value
Experimental group
(n ¼ 28)
Healthy controls
(n ¼ 20)
Age 41.3 (6.6) 40.3 (10.9) .718
Male gender (%) 19 (67.9) 14 (70.0) .875
Partnership (%) 9 (32.1) 15 (75.0) .003
Employment (%) 11 (39.3) 20 (100.0) .000
Doses of heroin (mg/day) 318.6 (131.7) —
Duration of dependence (years) 20.8 (6.6) —
Age at first heroin use (years) 19.0 (3.4) —
Duration of opioid maintenance (years) 6.7 (4.5) —
Substance use
Tobacco (%) 28 (100.0) 20 (100.0) 1.000
Number of cigarettes/day 21.0 (9.1) 11.5 (8.2) <.001
Cocaine (%) 15 (53.6) 0 (.0) <.001
Cannabis (%) 8 (28.6) 5 (25.0) .53
SD ¼ standard deviation.
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Table 1 gives an overview of the diagnostic and socio‐
demographic characteristics of the study sample.
Procedure
The present study is a randomized placebo‐controlled
crossover clinical trial. This study has been registered by the
website http://clinicaltrials.gov (ID NCT01174927). Heroin‐
dependent patients were informed that they would receive their
half‐daily dose of heroin or placebo before or after the
experiment. Allocation to both groups was randomized. One
week later, the patients completed the other condition with the
opposite sequence of substance administration. Healthy
controls only participated in the placebo‐session. After
completion of the baseline data assessment and urine drug
testing, heroin‐dependent patients administered their regular
half‐daily heroin dose (mean 319 mg/day ¼ 80 mg metha-
done equivalent) or the same amount of liquid of saline through
an indwelling intravenous catheter over a period of 30 seconds.
Healthy controls were injected 5 ml of saline. Heroin
(diacetylmorphine) was provided by the Swiss Federal
Office of Public Health in the form of hydrochloride salt. It
was dissolved in sterile water on site and aspirated into a
syringe, adapted to the evacuated infusion system. This
administration procedure is described in detail by Stohler
et al.27 The patients and the experimenter were blind to the
administered substance. Five minutes after substance injection,
patients reported their “rush” and their withdrawal level on
visual analog scales (VAS). Sixty minutes after substance
injection, patients filled out VAS for intoxication and sedation
level and a second data assessment to measure their emotional
state.
Data Assessments
The Heroin Craving Questionnaire (HCQ)28 was used to
measure heroin craving. A reliability of a ¼ .94 was
calculated. The corresponding scale contains nine items and
measures the desire to use heroin. The Beck Depression
Inventory (BDI), a 21‐question multiple‐choice self‐report
inventory, was used to assess the depressiveness, with a score
above 14 indicating mild depression.29 The state‐trait anxiety
inventory (STAI) was administered; this includes two well
validated 20‐item scales, with separate measures of state
and trait anxiety.30 The author notes that state anxiety may
fluctuate over time and can vary in intensity. Trait anxiety
indicates relatively stable individual anxiety proneness, and
refers to a general tendency to respond with anxiety to
perceived threats in the environment. The state‐trait anger
expression inventory‐2 (STAXI)31 was used to assess anger.
The 57‐item inventory measures the intensity of anger as an
emotional state (State Anger) and the disposition to experience
angry feelings as a personality trait (Trait Anger). The 60‐item
Likert‐scale short version of the adjective mood rating scale
(AMRS)32 was used to assess emotional excitation and well‐
being as two emotional domains of the AMRS. Good validity
and reliability have consistently been demonstrated for all
questionnaires.
Data Analysis
Statistical analyses were conducted using SPSS for
Windows (version 19). Descriptive data were analyzed by
means of unpaired t‐tests for continuous variables or x2 tests
for discrete variables, where appropriate. Group differences in
trait variables at baseline (depression score, trait anxiety, trait
anger) were examined using one‐way analysis of variance
(ANOVA) with three group levels (heroin, placebo, and
controls). State variables were analyzed by repeated‐measures
ANOVAwith two time points (baseline and 60 minutes later),
with within‐subjects or group factors (heroin, placebo, and
controls) and between‐subjects factor. The intoxication and
sedation level were used as covariates. The order of the
substance administration was randomized between subjects.
To protect against violations of sphericity, repeated‐measures
data were adjusted for within‐factor degrees of freedom using
Huynh–Feldt corrections, where appropriate. Where the
within‐subject factor was significant, post hoc planned t‐tests
comparisons were performed to identify significant differ-
ences. All statistical tests were considered significant at a two‐
tailed level of p < .05.
RESULTS
Affects and Mood at Baseline
Before substance administration, at baseline, heroin‐
dependent patients exhibited significantly higher depression
scores than the healthy controls (t ¼ 7.10, df ¼ 46,
p < .0001), with an average score of 14, and higher trait
anxiety (t ¼ 5.75, df ¼ 46, p < .0001). The trait anger level
did not differ significantly between the groups.
Drug Effects, Withdrawal Symptoms, and
Heroin Craving
Significantly more drug effects and fewer withdrawal
symptoms were reported immediately after heroin injection
than after placebo (p < .0001). Only one placebo effect
was observed, as one patient rated saline as heroin. After
placebo injection, heroin craving did not change over time.
After heroin administration, craving decreased significantly
(t ¼ 5.19, df ¼ 27, p < .0001). Compared to placebo,
significantly lower craving was reported at the end of
the experiment when patients received heroin (t ¼ 5.63,
df ¼ 27, p < .0001).
Effects of Heroin on State Anxiety
Repeated‐measures ANOVA showed a significant time
effect [F ¼ 13.06, p ¼ .001], a significant group effect [F ¼
14.71, p ¼ <.0001], and most importantly, a significant
interaction effect [F ¼ 5.18, p ¼ .008] for state anxiety.
There was no effect of subjective intoxication or sedation. As
shown in Table 2, state anxiety decreased after heroin
administration [t ¼ 6.16, df ¼ 27, p < .0001], but not after
placebo. After heroin administration, patients did not differ
from healthy controls at the end of the experiment. After
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placebo administration, heroin‐dependent patients also had a
higher anxiety level than healthy controls [t ¼ 5.06, df ¼ 45,
p < .0001].
Effects of Heroin on State Anger
According to the ANOVA, state anger showed a significant
group effect [F ¼ 14.71, p ¼ <.0001], and a significant
interaction effect [F ¼ 5.18, p ¼ .008]. The intoxication and
sedation level had no significant influence. After the
administration of heroin, anger decreased significantly
[t ¼ 6.16, df ¼ 27, p < .0001], whereas it increased after
placebo administration [t ¼ 2.11, df ¼ 27, p ¼ .044].
Table 2 shows that after placebo the patients had significantly
higher anger levels than healthy controls [t ¼ 2.83, df ¼ 46,
p ¼ .007].
Effects of Heroin on Emotional Excitation
There was a significant group effect [F ¼ 11.70,
p ¼ <.0001], and a significant interaction effect [F ¼ 21.98,
p < .0001] for emotional excitation. The covariates intoxica-
tion and sedation had no significant effect. After heroin, but not
after placebo, the emotional excitation level decreased
significantly [t ¼ 4.62, df ¼ 27, p < .0001] and no longer
differed from healthy controls (Table 2).
Effects of Heroin on Well‐being
ANOVA showed a significant group effect [F ¼ 13.03,
p ¼ <.0001] and a significant interaction effect [F ¼ 4.20,
p ¼ .019] for well‐being. There was no significant influence of
the covariates intoxication and sedation. The well‐being levels
increased significantly after heroin administration [t ¼ 3.58,
df ¼ 27, p ¼ .001]. The patients rated their well‐being higher
after heroin than after placebo [t ¼ 3.31, df ¼ 27, p ¼ .002].
After heroin administration, well‐being reached the level of
healthy controls (Table 2).
DISCUSSION
To our knowledge, this is the first study to examine the acute
effects of heroin on emotions in heroin‐dependent patients
compared to placebo and healthy controls.
We found that all negative emotions—including heroin
craving—decreased, whereas well‐being increased after heroin
administration to heroin‐dependent patients; this was irre-
spective of their perceived intoxication and sedation level.
When they had received heroin, the emotions of the heroin‐
dependent patient no longer differed from those of healthy
controls. The negative emotions were higher when they
TABLE 2. Mood and affects of the study sample
 )DS( naeM
 stnemerusaeM
p-Value 
group differences 
Experimental 
group with heroin 
(n = 28) 
Experimental 
group with placebo 
(n = 28) 
Controls 
with placebo 
(n = 20) 
State anxiety 
  Before substance application
 
Pat + placebo vs. 
   31.7 (4.6)     43.7 (8.9)    41.9 (10.0) 
Controls: *** 
  60 min after substance application     30.6 (5.4)     42.3 (9.3) 35.11 (7.4) *** 
State anger 
  Before substance application     12.0 (2.6) 
Pat + placebo vs. 
   10.1 (0.3)     11.3 (2.2) 
Controls: ** 
  60 min after substance application        12.9 (4.0)     *           10.3 (1.1)  10.3 (1.0) *** 
Emotional excitation 
  Before substance application     19.2 (5.8) 
Pat + placebo vs. 
   14.3 (2.3)     18.9 (5.7) 
Controls: *** 
  60 min after substance application     15.3 (3.3) ***     21.9 (6.8) ***    13.7 (2.8) 
Well-being 
   15.8 (4.0)   Before substance application 
Pat + placebo vs. 
   20.6 (5.2)     15.8 (3.8) 
Controls: *** 
  60 min after substance application      20.5 (4.1)     15.1 (3.8)  18.4 (3.9) *** 
SD ¼ standard deviation; *p < .05; **p < .01; ***p < .001.
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received saline. These findings may highlight the acute
emotional regulation effect of heroin in stable opioid‐
maintained heroin‐dependent patients.
The role of heroin as an emotional modulator has been
discussed in the development and maintenance of drug
addiction. Our findings were consistent with previous studies,
showing a higher level of anxiety and depressive features in
heroin addicts compared to healthy controls, and possibly
indicating affective vulnerability.18,19 This vulnerability could
be associated with less tolerance and ability to cope with
emotional stress. Therefore heroin may be needed as auxiliary
support, as our results show alignment of emotions to the
healthy controls.
It has been found that current opioid users without any
withdrawal symptoms had a higher emotional response to
unpleasant emotional stimuli images than healthy participants
and lower response to pleasant images than abstinent former
users.33 Moreover, using functional imaging, heroin addicts
showed a greater neural response to negative emotional stimuli
than to positive stimuli, whereas healthy controls showed the
opposite pattern.19 In other psychiatric illnesses associated
with disturbed affective regulation, for example, depression
and borderline personality disorder, the endogenous opioid
system involved in representation and regulation of emotion
showed modified responses to emotional challenges.34,35
The neurophysiological effects of opiates in human brains
have been studied thoroughly. It is known that opioids—such
as diacetylmorphine—unfold their effects on different opioid‐
receptors, the µ‐receptor being assumed to play an important
role in addiction.36 Broad expression of µ‐opioid receptors is
found in brain areas involved in the initiation and maintenance
of drug dependence. In the early stage of drug (ab)use the
reward system is activated (nucleus accumbens, ventral
tegmental area), whereas continued substance abuse leads to
dysregulation of the reward system.37 Other brain circuits
involved in the stress‐system and the obsessive‐compulsive
system then become more active (amygdala, hippocampus,
anterior cingulate, prefrontal cortex), resulting in altered
emotional states and processing, recurring craving for the
substance and failed impulse suppression.36,38
The use of opioids leads to physiological symptoms
(analgesia, sedation, hypothermia, miosis), as well as to
subjective perceived effects.39,40 Kosel et al.39 described a
short rush‐sensation immediately after intravenous heroin
administration and a period of euphoria after 15 minutes. Our
findings show higher negative emotions before substance
administration and normalization following the drug adminis-
tration and are in line with these previous studies on
neurobiological concepts of addiction.
On the assumption that there is altered processing of
affective stimuli and evoked emotional response in opioid
users, heroin could be effective in correcting emotional
dysregulation, and attenuating unpleasant affective states, as
our findings showed that administration of heroin dampens
negative emotions, including craving. The use of heroin could
be considered as a kind of self‐medication to balance the
affective homeostasis and constitutional or acquired emotional
vulnerability of the addicted brain.41 It has been shown that
acute administration of opioids suppresses cortisol levels and
leads to a reduction in craving in heroin‐dependent pa-
tients.42,43 Moreover, the first neuroimaging studies investi-
gating the acute effects of oral opioid administration on brain
function showed reduced activity in limbic brain areas during
drug‐related cues following methadone44 and buprenorphine
administration45 indicating emotional regulation from regular
opioid substitution. In our study, after heroin administration,
the emotional states of heroin‐dependent patients aligned with
those of healthy controls.
Other psychotropic substances also show significant effects
on emotional modulation. The reduction in negative affects
(eg, stress, tension, anxiety) is a known acute effect of alcohol
consumption.46–49 It appears that the emotional imbalance of
heroin addicts is even more severe than in addicts to other
substances which dampen negative emotions and that heroin
addicts have an even greater need to suppress negative
emotions. Moreover, many heroin addicts live in a stressful
environment under adverse circumstances (eg, homelessness,
prostitution, illegality/delinquency, social isolation), with
constant exposure to negative stimuli in the course of
increasing drug use.50 This ongoing stressor may therefore
sustain the desire for repeated drug use.
The pattern of heroin use is characterized by recurrent
craving for the substance. It has been found that the increase in
negative affects, such as sadness and anger, was significantly
associated with drug craving.17 Therefore it is possible that a
reduction in heroin craving is associated with a reduction in
negative emotions. However, this association does not
demonstrate causality.
Generally, drug addiction shows attributes of both impul-
sive (rapid and unplanned action regardless of the consequen-
ces) and compulsive behavior (perseveration despite negative
outcome).1 The development of the addiction has been seen as
a progression from impulsivity to compulsivity.51 During this
process, the motivational drive changes. Whereas the early
impulsive drug use is positively reinforced by generating
pleasant effects, the ongoing substance use is characterized by
the intention to eliminate negative emotions and unpleasant
craving, negative reinforcement being the driving force of this
vicious circle. The findings of our study on stable opioid‐
maintained heroin‐addicted patients with a long history of drug
use, suggest that dampening of negative emotions is a relevant
factor for maintaining the drug use in an advanced stage of the
addiction.
We did not observe opioid withdrawal symptoms during the
experiment. Moreover, withdrawal symptoms were generally
not expected at a methadone equivalent dosage of over 25 mg/
day.52 Our patients were in stable HAT and were informed that
they would receive their regular half‐daily heroin (40 mg
methadone equivalent dose on average) at the latest 60 minutes
after the first substance injection.
Our findings are limited by the moderate sample size and
the varying doses of administered heroin. However, the
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individually prescribed half‐daily heroin doses were estab-
lished during the heroin‐assisted treatment, on the basis of the
patient’s personal needs and had not been changed before the
study. Due to the cross‐over design of the study, patients knew
the sequence of the administered substance when attending
the second session of the experiment, and were therefore
unblinded. However, in our experimental study we were able
to examine the acute effect of heroin administration on
emotions in a controlled setting, whereas previous studies
were often based on retrospective assessments under less
controlled conditions, for example, unknown substances in
street heroin.
Our patients were recruited from a population which mainly
consisted of individuals with long‐standing polysubstance use.
Although this problem is virtually inevitable when chronic
heroin‐dependent individuals are examined, it may have biased
the results. The findings may thus not apply to all groups of
heroin users and maintenance patients.
These limitations notwithstanding, we think our results
retain significant clinical implications. This article could serve
as an up‐to‐date confirmation of a widely observed clinical
phenomenon. Heroin‐dependent patients have higher levels of
negative emotions in the absence of the drug. We could
demonstrate the positive effect on emotional regulation, even
1 hour after heroin administration. Acute heroin administration
dampens craving and negative emotions and leads to
normalization of the impaired emotions in heroin‐dependent
patients. Our findings emphasize the benefits of opioid
maintenance treatment for heroin‐dependent patients.
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